Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15900474,flow rate,The perfusate is perfused at a flow rate of 5 microL min(-1).,Microdialysis sampling and high-performance liquid chromatography with chemiluminescence detection for in-vivo on-line determination and study of the pharmacokinetics of levodopa in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900474/),[μl] / [min],5,93,DB01235,Levodopa
,15900474,detection limit (3sigma),The response of the system is linearly related to the concentration of levodopa in the range 1 x 10(-8) to 1 x 10(-6) g mL(-1) (r2 = 0.9995) with a detection limit (3sigma) of 3 x 10(-9) g mL(-1) and sample throughput of 12 h(-1); RSD is 2.8% (n = 11).,Microdialysis sampling and high-performance liquid chromatography with chemiluminescence detection for in-vivo on-line determination and study of the pharmacokinetics of levodopa in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900474/),[g] / [ml],3 x 10(-9),94,DB01235,Levodopa
,15900474,sample throughput,The response of the system is linearly related to the concentration of levodopa in the range 1 x 10(-8) to 1 x 10(-6) g mL(-1) (r2 = 0.9995) with a detection limit (3sigma) of 3 x 10(-9) g mL(-1) and sample throughput of 12 h(-1); RSD is 2.8% (n = 11).,Microdialysis sampling and high-performance liquid chromatography with chemiluminescence detection for in-vivo on-line determination and study of the pharmacokinetics of levodopa in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900474/),1/[h],12,95,DB01235,Levodopa
,15900474,Cmax,"The method has been successfully used to study the pharmacokinetics of levodopa in vivo; the values of the pharmacokinetics parameters Cmax, AUC(0-t) and Tmax were 16.60, 20.92 ng mL(-1), and 90 min, respectively.",Microdialysis sampling and high-performance liquid chromatography with chemiluminescence detection for in-vivo on-line determination and study of the pharmacokinetics of levodopa in blood. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900474/),[ng] / [ml],16.60,96,DB01235,Levodopa
,15900474,AUC(0-t),"The method has been successfully used to study the pharmacokinetics of levodopa in vivo; the values of the pharmacokinetics parameters Cmax, AUC(0-t) and Tmax were 16.60, 20.92 ng mL(-1), and 90 min, respectively.",Microdialysis sampling and high-performance liquid chromatography with chemiluminescence detection for in-vivo on-line determination and study of the pharmacokinetics of levodopa in blood. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900474/),[ng] / [ml],20.92,97,DB01235,Levodopa
,15900474,Tmax,"The method has been successfully used to study the pharmacokinetics of levodopa in vivo; the values of the pharmacokinetics parameters Cmax, AUC(0-t) and Tmax were 16.60, 20.92 ng mL(-1), and 90 min, respectively.",Microdialysis sampling and high-performance liquid chromatography with chemiluminescence detection for in-vivo on-line determination and study of the pharmacokinetics of levodopa in blood. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900474/),min,90,98,DB01235,Levodopa
,1768561,area under the plasma concentration-time curves (AUC),The area under the plasma concentration-time curves (AUC) for the final dose of levodopa (150.8 +/- 22.0 micrograms ml-1 min) was lower than for the two preceding doses (205.7 +/- 41.8 and 199.5 +/- 51.8 micrograms ml-1 min) but not different from that of the single dose given at the same time of day (141.7 +/- 29.1 micrograms ml-1 min).,Gastric emptying in healthy volunteers after multiple doses of levodopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768561/),[min·μg] / [ml],150.8,3087,DB01235,Levodopa
,1768561,area under the plasma concentration-time curves (AUC),The area under the plasma concentration-time curves (AUC) for the final dose of levodopa (150.8 +/- 22.0 micrograms ml-1 min) was lower than for the two preceding doses (205.7 +/- 41.8 and 199.5 +/- 51.8 micrograms ml-1 min) but not different from that of the single dose given at the same time of day (141.7 +/- 29.1 micrograms ml-1 min).,Gastric emptying in healthy volunteers after multiple doses of levodopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768561/),[min·μg] / [ml],205.7,3088,DB01235,Levodopa
,1768561,area under the plasma concentration-time curves (AUC),The area under the plasma concentration-time curves (AUC) for the final dose of levodopa (150.8 +/- 22.0 micrograms ml-1 min) was lower than for the two preceding doses (205.7 +/- 41.8 and 199.5 +/- 51.8 micrograms ml-1 min) but not different from that of the single dose given at the same time of day (141.7 +/- 29.1 micrograms ml-1 min).,Gastric emptying in healthy volunteers after multiple doses of levodopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768561/),[min·μg] / [ml],199.5,3089,DB01235,Levodopa
,1768561,area under the plasma concentration-time curves (AUC),The area under the plasma concentration-time curves (AUC) for the final dose of levodopa (150.8 +/- 22.0 micrograms ml-1 min) was lower than for the two preceding doses (205.7 +/- 41.8 and 199.5 +/- 51.8 micrograms ml-1 min) but not different from that of the single dose given at the same time of day (141.7 +/- 29.1 micrograms ml-1 min).,Gastric emptying in healthy volunteers after multiple doses of levodopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768561/),[min·μg] / [ml],141.7,3090,DB01235,Levodopa
< or =,15613930,AUC,"However, significant increases in AUC and Cmax, and a significant reduction in Tmax by adding AsA were observed in 25 patients with baseline AUC < or =2500 ng.hour/mL.",The effect of ascorbic acid on the pharmacokinetics of levodopa in elderly patients with Parkinson disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15613930/),[h·ng] / [ml],2500,8056,DB01235,Levodopa
,2685650,time to peak levodopa concentration,"Compared to standard Sinemet 25/100, time to peak levodopa concentration (2.3 versus 1.1 hrs), onset of maximal clinical improvement (2.2 versus 1.1 hrs), and other indices were significantly delayed with Sinemet CR.",Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685650/),h,2.3,10955,DB01235,Levodopa
,2685650,time to peak levodopa concentration,"Compared to standard Sinemet 25/100, time to peak levodopa concentration (2.3 versus 1.1 hrs), onset of maximal clinical improvement (2.2 versus 1.1 hrs), and other indices were significantly delayed with Sinemet CR.",Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685650/),h,1.1,10956,DB01235,Levodopa
,2685650,onset of maximal clinical improvement,"Compared to standard Sinemet 25/100, time to peak levodopa concentration (2.3 versus 1.1 hrs), onset of maximal clinical improvement (2.2 versus 1.1 hrs), and other indices were significantly delayed with Sinemet CR.",Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685650/),h,2.2,10957,DB01235,Levodopa
,2685650,onset of maximal clinical improvement,"Compared to standard Sinemet 25/100, time to peak levodopa concentration (2.3 versus 1.1 hrs), onset of maximal clinical improvement (2.2 versus 1.1 hrs), and other indices were significantly delayed with Sinemet CR.",Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685650/),h,1.1,10958,DB01235,Levodopa
,8836933,relative bioavailability,"The relative bioavailability of levodopa in plasma was 69% for the combination of SR and IR levodopa release, for the pure SR formulations (100 mg levodopa) 54% and (200 mg levodopa) 55%, compared to the 100% of the standard form of IR release of 100 mg levodopa.",Sustained-release of levodopa: single dose study of a new formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8836933/),%,69,11889,DB01235,Levodopa
,8836933,relative bioavailability,"The relative bioavailability of levodopa in plasma was 69% for the combination of SR and IR levodopa release, for the pure SR formulations (100 mg levodopa) 54% and (200 mg levodopa) 55%, compared to the 100% of the standard form of IR release of 100 mg levodopa.",Sustained-release of levodopa: single dose study of a new formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8836933/),%,54,11890,DB01235,Levodopa
,8836933,relative bioavailability,"The relative bioavailability of levodopa in plasma was 69% for the combination of SR and IR levodopa release, for the pure SR formulations (100 mg levodopa) 54% and (200 mg levodopa) 55%, compared to the 100% of the standard form of IR release of 100 mg levodopa.",Sustained-release of levodopa: single dose study of a new formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8836933/),%,55,11891,DB01235,Levodopa
,8836933,relative bioavailability,"The relative bioavailability of levodopa in plasma was 69% for the combination of SR and IR levodopa release, for the pure SR formulations (100 mg levodopa) 54% and (200 mg levodopa) 55%, compared to the 100% of the standard form of IR release of 100 mg levodopa.",Sustained-release of levodopa: single dose study of a new formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8836933/),%,100,11892,DB01235,Levodopa
,8726541,duration of motor response,"The duration of motor response to levodopa increased significantly from 2.3 h to 3.2 h (i.e., by 39%) after a single dose and to 3.4 h (i.e., by 48%) after 4 weeks' medication with entacapone.","Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726541/),h,2.3,12397,DB01235,Levodopa
,8726541,duration of motor response,"The duration of motor response to levodopa increased significantly from 2.3 h to 3.2 h (i.e., by 39%) after a single dose and to 3.4 h (i.e., by 48%) after 4 weeks' medication with entacapone.","Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726541/),h,3.2,12398,DB01235,Levodopa
,8726541,duration of motor response,"The duration of motor response to levodopa increased significantly from 2.3 h to 3.2 h (i.e., by 39%) after a single dose and to 3.4 h (i.e., by 48%) after 4 weeks' medication with entacapone.","Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726541/),h,3.4,12399,DB01235,Levodopa
,25875940,bioavailability,Levodopa bioavailability was 99 % for LCIG relative to LC-oral.,Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25875940/),%,99,13683,DB01235,Levodopa
,7565822,bioavailability,"The mean bioavailability varied between 14.7% and 40.2%, which was the bioavailability until the end of clinical benefit.",Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7565822/),%,14.7,13684,DB01235,Levodopa
,7565822,bioavailability,"The mean bioavailability varied between 14.7% and 40.2%, which was the bioavailability until the end of clinical benefit.",Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7565822/),%,40.2,13685,DB01235,Levodopa
,7565822,Cmax,"Also, despite the differences in dose, the values of the Cmax were similar, with average values of 12.7-25.6 ng/ml.",Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7565822/),[ng] / [ml],12.7-25.6,13686,DB01235,Levodopa
,7565822,Tmax,"Wide differences in Tmax were observed, with values varying between 16 min for the enema and 127.5 min for the Witepsol-H15 100-mg suppository.",Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7565822/),min,16,13687,DB01235,Levodopa
,7565822,Tmax,"Wide differences in Tmax were observed, with values varying between 16 min for the enema and 127.5 min for the Witepsol-H15 100-mg suppository.",Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7565822/),min,127.5,13688,DB01235,Levodopa
,7565822,onset time,"Onset of effect was similar for each of the preparations, with an average onset time of 14-28 min.",Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7565822/),min,14-28,13689,DB01235,Levodopa
,7565822,duration of effect,The duration of effect after administration of the Witepsol-H15 100-mg suppository was 156 +/- 43 min versus 50 +/- 13 min after rectal administration of the apomorphine solution.,Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7565822/),min,156,13690,DB01235,Levodopa
,7565822,duration of effect,The duration of effect after administration of the Witepsol-H15 100-mg suppository was 156 +/- 43 min versus 50 +/- 13 min after rectal administration of the apomorphine solution.,Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7565822/),min,50,13691,DB01235,Levodopa
,9754991,initial lag time,"After an initial lag time of 0.5 h, tolcapone was rapidly absorbed (peak plasma concentrations were reached within approximately 2 h) following either zero- or first-order absorption kinetics.","Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754991/),h,0.5,17888,DB01235,Levodopa
,9754991,absolute bioavailability,The absolute bioavailability of an oral dose was approximately 60%.,"Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754991/),%,60,17889,DB01235,Levodopa
,9754991,volume of distribution,"The volume of distribution was approximately 9 1, and the total clearance was approximately 71.h-l, resulting in a mean plasma half-life of 1.8 h.","Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754991/),1,9,17890,DB01235,Levodopa
,9754991,total clearance,"The volume of distribution was approximately 9 1, and the total clearance was approximately 71.h-l, resulting in a mean plasma half-life of 1.8 h.","Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754991/),h-l,71.,17891,DB01235,Levodopa
,9754991,plasma half-life,"The volume of distribution was approximately 9 1, and the total clearance was approximately 71.h-l, resulting in a mean plasma half-life of 1.8 h.","Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754991/),h,1.8,17892,DB01235,Levodopa
,30977301,Tmax,"For both formulations, the median Tmax for levodopa was 1.0 and 3.0 hours for carbidopa.",Levodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30977301/),h,1.0,19348,DB01235,Levodopa
,30977301,Tmax,"For both formulations, the median Tmax for levodopa was 1.0 and 3.0 hours for carbidopa.",Levodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30977301/),h,3.0,19349,DB01235,Levodopa
,30977301,half-life,The levodopa half-life harmonic mean was 1.6 hour for both formulations.,Levodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30977301/),h,1.6,19350,DB01235,Levodopa
,30977301,half-life,"The carbidopa half-life harmonic mean was 1.9 and 2.0 hour, respectively, for the LCIG-HV and LCIG-LV formulations.",Levodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30977301/),h,1.9,19351,DB01235,Levodopa
,30977301,half-life,"The carbidopa half-life harmonic mean was 1.9 and 2.0 hour, respectively, for the LCIG-HV and LCIG-LV formulations.",Levodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30977301/),h,2.0,19352,DB01235,Levodopa
,20661024,time at which the maximum peaks,"The time at which the maximum peaks occurred was delayed from 25 (15-240) to 105 (20-240) minutes, respectively.",Circadian rhythmicity in levodopa pharmacokinetics in patients with Parkinson disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20661024/),min,25,22114,DB01235,Levodopa
,20661024,time at which the maximum peaks,"The time at which the maximum peaks occurred was delayed from 25 (15-240) to 105 (20-240) minutes, respectively.",Circadian rhythmicity in levodopa pharmacokinetics in patients with Parkinson disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20661024/),min,105,22115,DB01235,Levodopa
,7381698,absolute bioavailability,"The absolute bioavailability of orally administered levodopa was estimated to be about 35% in both dogs and patients; however, the total amount absorbed of intact drug and levodopa metabolites was estimated to be 80--90% of the administered dose.",Dosage form design for improvement of bioavailability of levodopa II: bioavailability of marketed levodopa preparations in dogs and parkinsonian patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7381698/),%,35,23555,DB01235,Levodopa
,7381698,total amount absorbed,"The absolute bioavailability of orally administered levodopa was estimated to be about 35% in both dogs and patients; however, the total amount absorbed of intact drug and levodopa metabolites was estimated to be 80--90% of the administered dose.",Dosage form design for improvement of bioavailability of levodopa II: bioavailability of marketed levodopa preparations in dogs and parkinsonian patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7381698/),%,80--90,23556,DB01235,Levodopa
,26536022,half-life,"It was quickly eliminated with a half-life of 0.520 to 0.793 hour, suggesting no accumulation during multiple-dose phase.",A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease: A Repeat Dose and Pharmacokinetic Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26536022/),h,0.520 to 0.793,27119,DB01235,Levodopa
,26536022,Cmax,The Cmax of apomorphine at effective dose was presumed to be approximately 20 ng/mL.,A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease: A Repeat Dose and Pharmacokinetic Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26536022/),[ng] / [ml],20,27120,DB01235,Levodopa
,26536022,effective blood concentration,"Two-hour interval injections did not cause reduced responses, and effective blood concentration was presumed to be approximately 20 ng/mL similar, to the previous study conducted at North America.",A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease: A Repeat Dose and Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26536022/),[ng] / [ml],20,27121,DB01235,Levodopa
,15496222,AUC(0-12 h),"Donepezil PK assessments of PD patients receiving levodopa/carbidopa were similar to the PK results from healthy controls who received donepezil HCl only (mean AUC(0-12 h)= 281.6 +/- 17.6 and 268.6 +/- 19.9 ng.h ml(-1), respectively).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),[h·ng] / [ml],281.6,28359,DB01235,Levodopa
,15496222,AUC(0-12 h),"Donepezil PK assessments of PD patients receiving levodopa/carbidopa were similar to the PK results from healthy controls who received donepezil HCl only (mean AUC(0-12 h)= 281.6 +/- 17.6 and 268.6 +/- 19.9 ng.h ml(-1), respectively).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),[h·ng] / [ml],268.6,28360,DB01235,Levodopa
,15496222,AUC(0-8 h),"Carbidopa PK were not significantly altered by the concomitant administration of multiple doses of donepezil HCl, compared with when PD patients received placebo (mean AUC(0-8 h)= 921.8 +/- 160 and 821.8 +/- 113 ng.h ml(-1), respectively).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),[h·ng] / [ml],921.8,28361,DB01235,Levodopa
,15496222,AUC(0-8 h),"Carbidopa PK were not significantly altered by the concomitant administration of multiple doses of donepezil HCl, compared with when PD patients received placebo (mean AUC(0-8 h)= 921.8 +/- 160 and 821.8 +/- 113 ng.h ml(-1), respectively).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),[h·ng] / [ml],821.8,28362,DB01235,Levodopa
,15496222,C(max),"Eight hours after donepezil HCl, however, only C(max) and t(max) were observed to change compared with when PD patients received placebo (mean C(max) = 2652 +/- 429 and 2077 +/- 276 ng ml(-1), respectively; mean t(max) = 1.7 +/- 0.4 and 2.9 +/- 0.5 h, respectively; P< or = 0.05).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),[ng] / [ml],2652,28363,DB01235,Levodopa
,15496222,C(max),"Eight hours after donepezil HCl, however, only C(max) and t(max) were observed to change compared with when PD patients received placebo (mean C(max) = 2652 +/- 429 and 2077 +/- 276 ng ml(-1), respectively; mean t(max) = 1.7 +/- 0.4 and 2.9 +/- 0.5 h, respectively; P< or = 0.05).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),[ng] / [ml],2077,28364,DB01235,Levodopa
,15496222,t(max),"Eight hours after donepezil HCl, however, only C(max) and t(max) were observed to change compared with when PD patients received placebo (mean C(max) = 2652 +/- 429 and 2077 +/- 276 ng ml(-1), respectively; mean t(max) = 1.7 +/- 0.4 and 2.9 +/- 0.5 h, respectively; P< or = 0.05).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),h,1.7,28365,DB01235,Levodopa
,15496222,t(max),"Eight hours after donepezil HCl, however, only C(max) and t(max) were observed to change compared with when PD patients received placebo (mean C(max) = 2652 +/- 429 and 2077 +/- 276 ng ml(-1), respectively; mean t(max) = 1.7 +/- 0.4 and 2.9 +/- 0.5 h, respectively; P< or = 0.05).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),h,2.9,28366,DB01235,Levodopa
,9390741,detection limits,"The within-run and between-run coefficients of variations, for the two compounds, were less than 10%, in both platelets and plasma; the detection limits for platelet levels of L-dopa and 3-OMD were 2 and 6 ng/10(9) platelets, respectively.",Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9390741/),[ng] / [10],2,29375,DB01235,Levodopa
,9390741,detection limits,"The within-run and between-run coefficients of variations, for the two compounds, were less than 10%, in both platelets and plasma; the detection limits for platelet levels of L-dopa and 3-OMD were 2 and 6 ng/10(9) platelets, respectively.",Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9390741/),[ng] / [10],6,29376,DB01235,Levodopa
,9390741,detection limits,"In plasma, the detection limits for L-dopa and 3-OMD were 1 and 3 ng/ml, respectively.",Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9390741/),[ng] / [ml],1,29377,DB01235,Levodopa
,9390741,detection limits,"In plasma, the detection limits for L-dopa and 3-OMD were 1 and 3 ng/ml, respectively.",Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9390741/),[ng] / [ml],3,29378,DB01235,Levodopa
,11981235,plasma levodopa concentration,Mean plasma levodopa concentration ranged between 0.45 to 7.07 microg/mL and peak concentrations between 0.95 to 13.75 microg/mL.,Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981235/),[μg] / [ml],0.45 to 7.07,31667,DB01235,Levodopa
,11981235,peak concentrations,Mean plasma levodopa concentration ranged between 0.45 to 7.07 microg/mL and peak concentrations between 0.95 to 13.75 microg/mL.,Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981235/),[μg] / [ml],0.95 to 13.75,31668,DB01235,Levodopa
,29059133,maximum plasma concentration,MK-0657 7 mg achieved the target mean maximum plasma concentration of 400 nM.,A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29059133/),nM,400,31926,DB01235,Levodopa
,11307044,Peak plasma L-Dopa levels,Peak plasma L-Dopa levels and area under the curve did not differ significantly between the first-ever dose and after 1 month of continuous treatment (0.9 +/- 0.1 vs.,"The pharmacokinetic profile of the ""first ever"" oral dose of levodopa in de novo patients with Parkinson's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307044/),,0.9,32478,DB01235,Levodopa
,28055204,oral bioavailability,"Both compounds displayed good pharmacokinetic properties with 63% and 61% oral bioavailability, respectively, in rat.","Design, Synthesis of Novel, Potent, Selective, Orally Bioavailable Adenosine A2A Receptor Antagonists and Their Biological Evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28055204/),%,63,34627,DB01235,Levodopa
,28055204,oral bioavailability,"Both compounds displayed good pharmacokinetic properties with 63% and 61% oral bioavailability, respectively, in rat.","Design, Synthesis of Novel, Potent, Selective, Orally Bioavailable Adenosine A2A Receptor Antagonists and Their Biological Evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28055204/),%,61,34628,DB01235,Levodopa
,15965309,AUC,"The mean (+/-SD) plasma levodopa AUC was 39% (P = 0.0001) higher with entacapone (11,802 +/- 1454 ng/hour/mL) compared with placebo (8465 +/- 927 ng/hour/mL).",Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15965309/),[ng] / [h·ml],"11,802",34890,DB01235,Levodopa
,15965309,AUC,"The mean (+/-SD) plasma levodopa AUC was 39% (P = 0.0001) higher with entacapone (11,802 +/- 1454 ng/hour/mL) compared with placebo (8465 +/- 927 ng/hour/mL).",Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15965309/),[ng] / [h·ml],8465,34891,DB01235,Levodopa
>,22632782,T(max),"The gastric emptying study showed that T(max) ((13)C)>60 min was more common in patients with a plasma levodopa peak at 2 hours (14/18, 69%) than in those with a plasma levodopa peak at 1 hour (4/13, 22%) (p<0.05), total of 50.7 ± 16.4 min in all 31 patients.",Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22632782/),min,60,35327,DB01235,Levodopa
,22632782,T(max),"The gastric emptying study showed that T(max) ((13)C)>60 min was more common in patients with a plasma levodopa peak at 2 hours (14/18, 69%) than in those with a plasma levodopa peak at 1 hour (4/13, 22%) (p<0.05), total of 50.7 ± 16.4 min in all 31 patients.",Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22632782/),min,50,35328,DB01235,Levodopa
,1922125,relative bioavailability,The relative bioavailability of SL apomorphine ranged from 10 to 22% of a parenteral apomorphine dose.,Absorption of apomorphine by various routes in parkinsonism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1922125/),%,10 to 22,35334,DB01235,Levodopa
less,1922125,bioavailable,"Oral apomorphine was less than 4% bioavailable, and the transdermal dose did not produce detectable plasma levels.",Absorption of apomorphine by various routes in parkinsonism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1922125/),%,4,35335,DB01235,Levodopa
,1922125,latency to effect,"Three patients with motor fluctuations responded to SL apomorphine, with a latency to effect of 20-40 min and a duration of effect of 15-100 min.",Absorption of apomorphine by various routes in parkinsonism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1922125/),min,20-40,35336,DB01235,Levodopa
,1922125,duration of effect,"Three patients with motor fluctuations responded to SL apomorphine, with a latency to effect of 20-40 min and a duration of effect of 15-100 min.",Absorption of apomorphine by various routes in parkinsonism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1922125/),min,15-100,35337,DB01235,Levodopa
,8785378,half-life,A half-life of approximately 70 min was observed following the administration of either dosage form.,Pharmacokinetics and relative bioavailability of selegiline in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785378/),min,70,40112,DB01235,Levodopa
,16320098,V1,"Population parameter estimates (geometric mean) and population parameter variability (PPV; SD of normal distribution) were V1 11.4 l/70 kg (0.44), CL 30.9 l/h/70 kg (0.25), V2 27.3 l/70 kg (0.27), and CL(ic) 34.6 l/h/70 kg (0.48).",Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16320098/),[l] / [70·kg],11.4,40352,DB01235,Levodopa
,16320098,CL,"Population parameter estimates (geometric mean) and population parameter variability (PPV; SD of normal distribution) were V1 11.4 l/70 kg (0.44), CL 30.9 l/h/70 kg (0.25), V2 27.3 l/70 kg (0.27), and CL(ic) 34.6 l/h/70 kg (0.48).",Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16320098/),[l] / [70·h·kg],30.9,40353,DB01235,Levodopa
,16320098,V2,"Population parameter estimates (geometric mean) and population parameter variability (PPV; SD of normal distribution) were V1 11.4 l/70 kg (0.44), CL 30.9 l/h/70 kg (0.25), V2 27.3 l/70 kg (0.27), and CL(ic) 34.6 l/h/70 kg (0.48).",Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16320098/),[l] / [70·kg],27.3,40354,DB01235,Levodopa
,16320098,CL(ic),"Population parameter estimates (geometric mean) and population parameter variability (PPV; SD of normal distribution) were V1 11.4 l/70 kg (0.44), CL 30.9 l/h/70 kg (0.25), V2 27.3 l/70 kg (0.27), and CL(ic) 34.6 l/h/70 kg (0.48).",Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16320098/),[l] / [70·h·kg],34.6,40355,DB01235,Levodopa
,2404503,time to 90% emptying,3. In the presence of levodopa the time to 90% emptying was prolonged from 32 +/- 24 min to 81 +/- 20 min (P less than 0.01).,The influence of levodopa on gastric emptying in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2404503/),min,32,42414,DB01235,Levodopa
,2404503,time to 90% emptying,3. In the presence of levodopa the time to 90% emptying was prolonged from 32 +/- 24 min to 81 +/- 20 min (P less than 0.01).,The influence of levodopa on gastric emptying in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2404503/),min,81,42415,DB01235,Levodopa
,1811168,Tmax,"The mean Tmax value of levodopa in plasma and muscle was 0.16 h and 1.0 h, respectively.",In vivo pharmacokinetics of levodopa and 3-O-methyldopa in muscle. A microdialysis study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1811168/),h,0.16,44183,DB01235,Levodopa
,1811168,Tmax,"The mean Tmax value of levodopa in plasma and muscle was 0.16 h and 1.0 h, respectively.",In vivo pharmacokinetics of levodopa and 3-O-methyldopa in muscle. A microdialysis study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1811168/),h,1.0,44184,DB01235,Levodopa
,20815935,cross-membrane permeability (Pm*),The cross-membrane permeability (Pm*) determined in rat jejunal perfusion of D-phenylglycine-L-dopa was higher than that of L-dopa (2.58 ± 0.14 vs. 0.94 ± 0.10).,Evidence of D-phenylglycine as delivering tool for improving L-dopa absorption. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20815935/),,2.58,44913,DB01235,Levodopa
,20815935,cross-membrane permeability (Pm*),The cross-membrane permeability (Pm*) determined in rat jejunal perfusion of D-phenylglycine-L-dopa was higher than that of L-dopa (2.58 ± 0.14 vs. 0.94 ± 0.10).,Evidence of D-phenylglycine as delivering tool for improving L-dopa absorption. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20815935/),,0.94,44914,DB01235,Levodopa
,2360790,distribution,"Although slower, the distribution and elimination half-lives for L-dopa from cisternal CSF (8.9 and 49.2 minutes, respectively) were of a similar magnitude to those from plasma (4.9 and 33.2 minutes, respectively).",L-dopa pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360790/),min,8.9,45941,DB01235,Levodopa
,2360790,distribution,"Although slower, the distribution and elimination half-lives for L-dopa from cisternal CSF (8.9 and 49.2 minutes, respectively) were of a similar magnitude to those from plasma (4.9 and 33.2 minutes, respectively).",L-dopa pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360790/),min,4.9,45942,DB01235,Levodopa
,2360790,elimination half-lives,"Although slower, the distribution and elimination half-lives for L-dopa from cisternal CSF (8.9 and 49.2 minutes, respectively) were of a similar magnitude to those from plasma (4.9 and 33.2 minutes, respectively).",L-dopa pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360790/),min,49.2,45943,DB01235,Levodopa
,2360790,elimination half-lives,"Although slower, the distribution and elimination half-lives for L-dopa from cisternal CSF (8.9 and 49.2 minutes, respectively) were of a similar magnitude to those from plasma (4.9 and 33.2 minutes, respectively).",L-dopa pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360790/),min,4.9,45944,DB01235,Levodopa
,2360790,elimination half-lives,"Although slower, the distribution and elimination half-lives for L-dopa from cisternal CSF (8.9 and 49.2 minutes, respectively) were of a similar magnitude to those from plasma (4.9 and 33.2 minutes, respectively).",L-dopa pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360790/),min,33.2,45945,DB01235,Levodopa
,2360790,elimination half-life,"In contrast to cisternal CSF, the disappearance of L-dopa from lumbar CSF fits an open, one-compartment model with an elimination half-life of 100 minutes.",L-dopa pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360790/),min,100,45946,DB01235,Levodopa
,9520073,Cmax,"The pharmacokinetics of levodopa and 3-OMD after one intact or two halved tablets were very similar with average Cmax and tmax 1.9 mg x l(-1) and 1.2 h, respectively.","Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9520073/),[mg] / [l],1.9,47997,DB01235,Levodopa
,9520073,tmax,"The pharmacokinetics of levodopa and 3-OMD after one intact or two halved tablets were very similar with average Cmax and tmax 1.9 mg x l(-1) and 1.2 h, respectively.","Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9520073/),[mg] / [l],1.9,47998,DB01235,Levodopa
,9520073,tmax,"The pharmacokinetics of levodopa and 3-OMD after one intact or two halved tablets were very similar with average Cmax and tmax 1.9 mg x l(-1) and 1.2 h, respectively.","Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9520073/),h,1.2,47999,DB01235,Levodopa
,9520073,Cmax,"Cmax and tmax were on average 2.1 mg x l(-1) and 1.3 h, respectively, in the fed condition and 1.5 mg x l(-1) and 2.5 h in the fasted condition.","Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9520073/),[mg] / [l],2.1,48000,DB01235,Levodopa
,9520073,Cmax,"Cmax and tmax were on average 2.1 mg x l(-1) and 1.3 h, respectively, in the fed condition and 1.5 mg x l(-1) and 2.5 h in the fasted condition.","Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9520073/),[mg] / [l],1.5,48001,DB01235,Levodopa
,9520073,tmax,"Cmax and tmax were on average 2.1 mg x l(-1) and 1.3 h, respectively, in the fed condition and 1.5 mg x l(-1) and 2.5 h in the fasted condition.","Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9520073/),h,1.3,48002,DB01235,Levodopa
,9520073,tmax,"Cmax and tmax were on average 2.1 mg x l(-1) and 1.3 h, respectively, in the fed condition and 1.5 mg x l(-1) and 2.5 h in the fasted condition.","Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9520073/),h,2.5,48003,DB01235,Levodopa
,15548480,onset of effect,"Compared with standard LD/CD, the 30 g mucuna preparation led to a considerably faster onset of effect (34.6 v 68.5 min; p = 0.021), reflected in shorter latencies to peak L-dopa plasma concentrations.",Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15548480/),min,34.6,53141,DB01235,Levodopa
,15548480,onset of effect,"Compared with standard LD/CD, the 30 g mucuna preparation led to a considerably faster onset of effect (34.6 v 68.5 min; p = 0.021), reflected in shorter latencies to peak L-dopa plasma concentrations.",Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15548480/),min,68.5,53142,DB01235,Levodopa
,8138904,maximum concentration (Cmax),"The mean maximum concentration (Cmax) for L-dopa in plasma was 173.10 +/- 9.85 ng/mL, whereas in skeletal muscle extracellular fluid, it was 14.56 +/- 2.27 ng/mL.",Simultaneous in vivo microdialysis in plasma and skeletal muscle: a study of the pharmacokinetic properties of levodopa by noncompartmental analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8138904/),[ng] / [ml],173.10,56813,DB01235,Levodopa
,8138904,maximum concentration (Cmax),"The mean maximum concentration (Cmax) for L-dopa in plasma was 173.10 +/- 9.85 ng/mL, whereas in skeletal muscle extracellular fluid, it was 14.56 +/- 2.27 ng/mL.",Simultaneous in vivo microdialysis in plasma and skeletal muscle: a study of the pharmacokinetic properties of levodopa by noncompartmental analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8138904/),[ng] / [ml],14.56,56814,DB01235,Levodopa
,12464717,maximum plasma concentration (C(max),"The pharmacokinetics of levodopa after a single-dose administration (day 1) of Madopar DR and Madopar HBS were significantly different as reflected by the respective mean values of maximum plasma concentration (C(max) 1.99 vs. 0.82 mg x l-1), time to reach maximum concentration (t(max) 0.7 vs.",Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),[mg] / [l],1.99,57497,DB01235,Levodopa
,12464717,maximum plasma concentration (C(max),"The pharmacokinetics of levodopa after a single-dose administration (day 1) of Madopar DR and Madopar HBS were significantly different as reflected by the respective mean values of maximum plasma concentration (C(max) 1.99 vs. 0.82 mg x l-1), time to reach maximum concentration (t(max) 0.7 vs.",Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),[mg] / [l],0.82,57498,DB01235,Levodopa
,12464717,time to reach maximum concentration (t(max),"The pharmacokinetics of levodopa after a single-dose administration (day 1) of Madopar DR and Madopar HBS were significantly different as reflected by the respective mean values of maximum plasma concentration (C(max) 1.99 vs. 0.82 mg x l-1), time to reach maximum concentration (t(max) 0.7 vs.",Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),,0.7,57499,DB01235,Levodopa
,12464717,area under the plasma concentration-time curve (AUC(0- infinity ),2.6 h) and area under the plasma concentration-time curve (AUC(0- infinity ) 4.52 vs. 3.18 mg x h x l-1).,Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),[h·mg] / [l],4.52,57500,DB01235,Levodopa
,12464717,area under the plasma concentration-time curve (AUC(0- infinity ),2.6 h) and area under the plasma concentration-time curve (AUC(0- infinity ) 4.52 vs. 3.18 mg x h x l-1).,Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),[h·mg] / [l],3.18,57501,DB01235,Levodopa
,12464717,C(max),The respective values after multiple doses (day 8) were: C(max) 1.98 vs.,Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),,1.98,57502,DB01235,Levodopa
,12464717,t(max),"0.93 mg x l-1, t(max) 0.7 vs.",Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),,0.7,57503,DB01235,Levodopa
,12464717,AUC(0-infinity ),2.3 h and AUC(0-infinity ) 4.84 vs.,Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),,4.84,57504,DB01235,Levodopa
,12464717,relative bioavailability,The relative bioavailability (Madopar DR vs. Madopar HBS) was 1.73 on day 1 and 1.32 on day 8.,Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),,1.73,57505,DB01235,Levodopa
,12464717,relative bioavailability,The relative bioavailability (Madopar DR vs. Madopar HBS) was 1.73 on day 1 and 1.32 on day 8.,Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),,1.32,57506,DB01235,Levodopa
,32554330,Cmax,"The Cmax of levodopa was 9.0 ± 4.0 ng/mL, Tmax was 41.4 ± 40.2 min, and area under the blood concentration-time curve up to 4 h (AUC4hr) was 12.3 ± 3.7 ng/mL*4hr.","Female, aging, difference formulations of DCI, or lower body weight increases AUC4hr of levodopa in patients with Parkinson's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32554330/),[ng] / [ml],9.0,58534,DB01235,Levodopa
,32554330,Tmax,"The Cmax of levodopa was 9.0 ± 4.0 ng/mL, Tmax was 41.4 ± 40.2 min, and area under the blood concentration-time curve up to 4 h (AUC4hr) was 12.3 ± 3.7 ng/mL*4hr.","Female, aging, difference formulations of DCI, or lower body weight increases AUC4hr of levodopa in patients with Parkinson's disease. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32554330/),min,41.4,58535,DB01235,Levodopa
,32554330,area under the blood concentration-time curve up to 4 h (AUC4hr),"The Cmax of levodopa was 9.0 ± 4.0 ng/mL, Tmax was 41.4 ± 40.2 min, and area under the blood concentration-time curve up to 4 h (AUC4hr) was 12.3 ± 3.7 ng/mL*4hr.","Female, aging, difference formulations of DCI, or lower body weight increases AUC4hr of levodopa in patients with Parkinson's disease. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32554330/),[ng] / [4hr·ml],12.3,58536,DB01235,Levodopa
,23229334,C(avg),"Mean (SD) C(avg) (μg/mL) were 2.9 (0.84) for levodopa, 17.1 (4.99) for 3-OMD, and 0.22 (0.08) for carbidopa.","Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229334/),[μg] / [ml],2.9,59538,DB01235,Levodopa
,23229334,C(avg),"Mean (SD) C(avg) (μg/mL) were 2.9 (0.84) for levodopa, 17.1 (4.99) for 3-OMD, and 0.22 (0.08) for carbidopa.","Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229334/),[μg] / [ml],17.1,59539,DB01235,Levodopa
,23229334,C(avg),"Mean (SD) C(avg) (μg/mL) were 2.9 (0.84) for levodopa, 17.1 (4.99) for 3-OMD, and 0.22 (0.08) for carbidopa.","Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229334/),[μg] / [ml],0.22,59540,DB01235,Levodopa
,34366380,steady-state exposure,Foslevodopa/foscarbidopa infusion provides stable LD and CD exposures compared to oral LD/CD dosing with the average steady-state exposure ranging from 747-4660 ng/mL for the different groups.,Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34366380/),[ng] / [ml],747-4660,60341,DB01235,Levodopa
,21856105,m/z,"Selected reaction monitoring was performed using the fragmentation transitions m/z 198→m/z 107, m/z 212→m/z 166 and m/z 227→m/z 181 for levodopa, 3-O-methyldopa and carbidopa, respectively.",Simultaneous quantitation of levodopa and 3-O-methyldopa in human plasma by HPLC-ESI-MS/MS: application for a pharmacokinetic study with a levodopa/benserazide formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21856105/),,212,60621,DB01235,Levodopa
,21856105,m/z,"Selected reaction monitoring was performed using the fragmentation transitions m/z 198→m/z 107, m/z 212→m/z 166 and m/z 227→m/z 181 for levodopa, 3-O-methyldopa and carbidopa, respectively.",Simultaneous quantitation of levodopa and 3-O-methyldopa in human plasma by HPLC-ESI-MS/MS: application for a pharmacokinetic study with a levodopa/benserazide formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21856105/),,166,60622,DB01235,Levodopa
,21856105,m/z,"Selected reaction monitoring was performed using the fragmentation transitions m/z 198→m/z 107, m/z 212→m/z 166 and m/z 227→m/z 181 for levodopa, 3-O-methyldopa and carbidopa, respectively.",Simultaneous quantitation of levodopa and 3-O-methyldopa in human plasma by HPLC-ESI-MS/MS: application for a pharmacokinetic study with a levodopa/benserazide formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21856105/),,227,60623,DB01235,Levodopa
,21856105,m/z,"Selected reaction monitoring was performed using the fragmentation transitions m/z 198→m/z 107, m/z 212→m/z 166 and m/z 227→m/z 181 for levodopa, 3-O-methyldopa and carbidopa, respectively.",Simultaneous quantitation of levodopa and 3-O-methyldopa in human plasma by HPLC-ESI-MS/MS: application for a pharmacokinetic study with a levodopa/benserazide formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21856105/),,181,60624,DB01235,Levodopa
higher,21856105,recovery rates,"The method shown to be specific, precise, accurate and provided recovery rates higher than 85% for all analytes.",Simultaneous quantitation of levodopa and 3-O-methyldopa in human plasma by HPLC-ESI-MS/MS: application for a pharmacokinetic study with a levodopa/benserazide formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21856105/),%,85,60625,DB01235,Levodopa
,16485914,elimination half-life (t(1/2)),The elimination half-life (t(1/2)) of levodopa from plasma (in combination with a decarboxylase inhibitor) of about 1.5 hours becomes more influential as the disease progresses.,Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16485914/),h,1.5,61864,DB01235,Levodopa
,24271646,inhibition (Emax),Maximum S-COMT inhibition (Emax) occurred earlier for the hepatically impaired group with values of 100 % and 91.2 % for the hepatically impaired and control groups respectively.,Effect of moderate liver impairment on the pharmacokinetics of opicapone. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24271646/),%,100,63114,DB01235,Levodopa
,24271646,inhibition (Emax),Maximum S-COMT inhibition (Emax) occurred earlier for the hepatically impaired group with values of 100 % and 91.2 % for the hepatically impaired and control groups respectively.,Effect of moderate liver impairment on the pharmacokinetics of opicapone. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24271646/),%,91.2,63115,DB01235,Levodopa
,33093598,apparent clearances (CL/F),"The final model was a one compartment model with a high fixed absorption rate constant, and a first order elimination, with estimated apparent clearances (CL/F), of 27.9 L/h/70 kg for LCIG versus 17.5 L/h/70 kg for LECIG, and apparent volume of distribution of 74.4 L/70 kg.",Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33093598/),[l] / [70·h·kg],27.9,64634,DB01235,Levodopa
,33093598,apparent clearances (CL/F),"The final model was a one compartment model with a high fixed absorption rate constant, and a first order elimination, with estimated apparent clearances (CL/F), of 27.9 L/h/70 kg for LCIG versus 17.5 L/h/70 kg for LECIG, and apparent volume of distribution of 74.4 L/70 kg.",Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33093598/),[l] / [70·h·kg],17.5,64635,DB01235,Levodopa
,33093598,apparent volume of distribution,"The final model was a one compartment model with a high fixed absorption rate constant, and a first order elimination, with estimated apparent clearances (CL/F), of 27.9 L/h/70 kg for LCIG versus 17.5 L/h/70 kg for LECIG, and apparent volume of distribution of 74.4 L/70 kg.",Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33093598/),[l] / [70·kg],74.4,64636,DB01235,Levodopa
,8780091,time of onset in,"The time of onset in clinical benefit was significantly earlier with Std-L (47 minutes, range 15 to 75 minutes) as the first dose as compared with L-CR (58 minutes, range 30 to 105 minutes).",Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780091/),min,47,64766,DB01235,Levodopa
,8780091,time of onset in,"The time of onset in clinical benefit was significantly earlier with Std-L (47 minutes, range 15 to 75 minutes) as the first dose as compared with L-CR (58 minutes, range 30 to 105 minutes).",Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780091/),min,58,64767,DB01235,Levodopa
,8780091,Tmax,"Similarly, there was a significant difference in the peak plasma dopa levels (Cmax) and the time to reach peak plasma dopa levels (Tmax) with administration of Std-L (Tmax 36 minutes; Cmax 1,501 micrograms/ml) as compared with L-CR (Tmax 111 minutes, Cmax 1,260 micrograms/ml).",Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780091/),min,36,64768,DB01235,Levodopa
,8780091,Cmax,"Similarly, there was a significant difference in the peak plasma dopa levels (Cmax) and the time to reach peak plasma dopa levels (Tmax) with administration of Std-L (Tmax 36 minutes; Cmax 1,501 micrograms/ml) as compared with L-CR (Tmax 111 minutes, Cmax 1,260 micrograms/ml).",Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780091/),[μg] / [ml],"1,501",64769,DB01235,Levodopa
,8780091,Tmax,"Similarly, there was a significant difference in the peak plasma dopa levels (Cmax) and the time to reach peak plasma dopa levels (Tmax) with administration of Std-L (Tmax 36 minutes; Cmax 1,501 micrograms/ml) as compared with L-CR (Tmax 111 minutes, Cmax 1,260 micrograms/ml).",Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780091/),min,111,64770,DB01235,Levodopa
,8780091,Cmax,"Similarly, there was a significant difference in the peak plasma dopa levels (Cmax) and the time to reach peak plasma dopa levels (Tmax) with administration of Std-L (Tmax 36 minutes; Cmax 1,501 micrograms/ml) as compared with L-CR (Tmax 111 minutes, Cmax 1,260 micrograms/ml).",Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780091/),[μg] / [ml],"1,260",64771,DB01235,Levodopa
,25869243,IC50,SAB inhibited the methylation of l-DOPA with an IC50 value of 2.08 μM in vitro.,Salvianolic acid B as a substrate and weak catechol-O-methyltransferase inhibitor in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25869243/),μM,2.08,66282,DB01235,Levodopa
,24339234,total daily off time,The mean total daily off time was reduced from baseline by a mean (± standard error) of 2.7 hours (± 0.48 hours) for immediate-release carbidopa-levodopa and 3.0 hours (± 0.57 hours) for XP21279-carbidopa (P = 0.49).,Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24339234/),h,2.7,66635,DB01235,Levodopa
,24339234,total daily off time,The mean total daily off time was reduced from baseline by a mean (± standard error) of 2.7 hours (± 0.48 hours) for immediate-release carbidopa-levodopa and 3.0 hours (± 0.57 hours) for XP21279-carbidopa (P = 0.49).,Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24339234/),h,3.0,66636,DB01235,Levodopa
,8133901,t 1/2 beta,The elimination half-life of L-dopa in the controls was higher in muscle (t 1/2 beta = 1.76 h) than in blood plasma (t 1/2 beta = 0.50 h).,The effect of carbidopa on the pharmacokinetics and metabolism of intravenously administered levodopa in blood plasma and skeletal muscle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8133901/),h,1.76,67810,DB01235,Levodopa
,8133901,t 1/2 beta,The elimination half-life of L-dopa in the controls was higher in muscle (t 1/2 beta = 1.76 h) than in blood plasma (t 1/2 beta = 0.50 h).,The effect of carbidopa on the pharmacokinetics and metabolism of intravenously administered levodopa in blood plasma and skeletal muscle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8133901/),h,0.50,67811,DB01235,Levodopa
,9695725,C50,"The second was C50(carbidopa) = 951 ng/ml; C50(benserazide) = 1238 ng/ml, where C50 is the steady-state plasma concentration of levodopa eliciting half of maximum attainable effect, and carbidopa and benserazide are the dopa decarboxylase inhibitors given in the study.",Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695725/),[ng] / [ml],951,69384,DB01235,Levodopa
,9695725,C50,"The second was C50(carbidopa) = 951 ng/ml; C50(benserazide) = 1238 ng/ml, where C50 is the steady-state plasma concentration of levodopa eliciting half of maximum attainable effect, and carbidopa and benserazide are the dopa decarboxylase inhibitors given in the study.",Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695725/),[ng] / [ml],1238,69385,DB01235,Levodopa
,7735206,total clearance,The total clearance of exogenous L-dopa in plasma was 3.13(l/h)/kg.,Pharmacokinetic and pharmacodynamic studies of L-dopa in rats. I. Pharmacokinetic analysis of L-dopa in rat plasma and striatum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735206/),[l] / [h)·kg],3.13,69856,DB01235,Levodopa
,7735206,production rate constant,The production rate constant of endogenous L-dopa in plasma was 6.59(mg/h)/kg.,Pharmacokinetic and pharmacodynamic studies of L-dopa in rats. I. Pharmacokinetic analysis of L-dopa in rat plasma and striatum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735206/),[mg] / [h)·kg],6.59,69857,DB01235,Levodopa
,18778758,gastric residence time,"It was shown that the three formulations offered almost the same mean gastric residence time, which was about 240 min.",Pharmacoscintigraphic and pharmacokinetic evaluation on healthy human volunteers of sustained-release floating minitablets containing levodopa and carbidopa. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18778758/),min,240,70100,DB01235,Levodopa
,8739811,halflife,"Despite the long halflife of 3-O-methyltolcapone (39 h), only minor accumulation occurred due to suppression of its formation by tolcapone.",Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739811/),h,39,70334,DB01235,Levodopa
,22377973,first maximum time,"Compared with C-ER, both gastroretentive ER tablets significantly extended the first maximum time (6.0 vs 2.5 h; P < 0.025) and had smoother plasma concentration-time profiles while achieving a similar maximum plasma concentration and area under the curve.",Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22377973/),h,6.0,71779,DB01235,Levodopa
,22377973,first maximum time,"Compared with C-ER, both gastroretentive ER tablets significantly extended the first maximum time (6.0 vs 2.5 h; P < 0.025) and had smoother plasma concentration-time profiles while achieving a similar maximum plasma concentration and area under the curve.",Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22377973/),h,2.5,71780,DB01235,Levodopa
,22377973,peak/trough ratio,PK modeling predicts a steady-state levodopa peak/trough ratio of 4 for both IR/ER and ER formulations and a ratio of 21 for C-ER.,Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22377973/),,4,71781,DB01235,Levodopa
,15039453,C(max),"Pulmonary administration of L-dopa (2 mg) to rats resulted in a rapid elevation of plasma levels (C(max) = 4.8 +/- 1.10 microg/ml at 2 min), whereas oral administration of L-dopa produced a much delayed and lower C(max) (1.8 +/- 0.40 microg/ml at 30 min).",A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15039453/),[μg] / [ml],4.8,72290,DB01235,Levodopa
,15039453,C(max),"Pulmonary administration of L-dopa (2 mg) to rats resulted in a rapid elevation of plasma levels (C(max) = 4.8 +/- 1.10 microg/ml at 2 min), whereas oral administration of L-dopa produced a much delayed and lower C(max) (1.8 +/- 0.40 microg/ml at 30 min).",A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15039453/),[μg] / [ml],1.8,72291,DB01235,Levodopa
,3428307,bioavailability,"Although the bioavailability after oral dosing is reduced as compared with standard Madopar (60-70%), this difference seems to be due to incomplete absorption rather than altered disposition of the drug.",Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid on the absorption of Madopar HBS in volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428307/),%,60-70,72523,DB01235,Levodopa
,3428307,bioavailability,"The presence or absence of food in the stomach has no effect on the absorption of L-dopa from Madopar HBS, but administration of antacids further reduces the bioavailability (45%).",Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid on the absorption of Madopar HBS in volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428307/),%,45,72524,DB01235,Levodopa
,2049250,AUC,"4. By contrast, the AUC for levodopa following the low protein meal (193.9 +/- 15.7 micrograms ml-1 min) was significantly lower compared with administration in the fasted state (216.5 +/- 26.1 micrograms ml-1 min).",The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049250/),[min·μg] / [ml],193.9,76030,DB01235,Levodopa
,2049250,AUC,"4. By contrast, the AUC for levodopa following the low protein meal (193.9 +/- 15.7 micrograms ml-1 min) was significantly lower compared with administration in the fasted state (216.5 +/- 26.1 micrograms ml-1 min).",The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049250/),[min·μg] / [ml],216.5,76031,DB01235,Levodopa
,9483165,plasma elimination half-life,"It has an appropriate receptor affinity profile, with potent and long-lasting dopaminergic stimulatory effects in 6-hydroxydopamine-lesioned rats and in MPTP (1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine)-lesioned primates; it has a consistent pharmacokinetic profile, with a very long mean plasma elimination half-life of 65 to 110 hours, and its absorption and excretion are unaffected by food, age or renal or hepatic disease; moreover, when given concomitantly, cabergoline does not influence levodopa pharmacokinetics.",Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9483165/),h,65 to 110,77725,DB01235,Levodopa
,28101657,time to maximum improvement,"The mean time to maximum improvement in sum of six UPDRS items score was 78 min (±59) (n = 16), and the mean time to TRS score maximum effect was 54 min (±51) (n = 15).",Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28101657/),min,78,78650,DB01235,Levodopa
,28101657,time to TRS score maximum effect,"The mean time to maximum improvement in sum of six UPDRS items score was 78 min (±59) (n = 16), and the mean time to TRS score maximum effect was 54 min (±51) (n = 15).",Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28101657/),min,54,78651,DB01235,Levodopa
,28101657,time to onset of dyskinesia,Mean time to onset of dyskinesia was 41 min (±38) (n = 13).,Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28101657/),min,41,78652,DB01235,Levodopa
,12942590,Tmax,Tmax (time at which the maximal L-DOPA concentration was reached) were 69 +/- 12 min and 64 +/- 11 min for Sinemet and Grifoparkin respectively (NS).,[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),min,69,79425,DB01235,Levodopa
,12942590,Tmax,Tmax (time at which the maximal L-DOPA concentration was reached) were 69 +/- 12 min and 64 +/- 11 min for Sinemet and Grifoparkin respectively (NS).,[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),min,64,79426,DB01235,Levodopa
,12942590,Cmax (maximal L-DOPA concentration reached,Cmax (maximal L-DOPA concentration reached) was 3161 +/- 345 ng/ml for Sinemet and 3274 +/- 520 ng/ml for Grifoparkin (NS).,[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),[ng] / [ml],3161,79427,DB01235,Levodopa
,12942590,Cmax (maximal L-DOPA concentration reached,Cmax (maximal L-DOPA concentration reached) was 3161 +/- 345 ng/ml for Sinemet and 3274 +/- 520 ng/ml for Grifoparkin (NS).,[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),[ng] / [ml],3274,79428,DB01235,Levodopa
,12942590,t1/2 (half life time),"The t1/2 (half life time), CL (clearance) and volume of distribution (Vd) values calculated were 159 +/- 32 min, 51.7 +/- 5.1 1/h and 3.6 +/- 1.2 l/kg for Sinemet and 161 +/- 48 min, 58.7 +/- 8 l/h and 3.0 +/- 0.7 l/kg for Grifoparkin (NS).",[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),min,159,79429,DB01235,Levodopa
,12942590,CL (clearance),"The t1/2 (half life time), CL (clearance) and volume of distribution (Vd) values calculated were 159 +/- 32 min, 51.7 +/- 5.1 1/h and 3.6 +/- 1.2 l/kg for Sinemet and 161 +/- 48 min, 58.7 +/- 8 l/h and 3.0 +/- 0.7 l/kg for Grifoparkin (NS).",[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),[1] / [h],51.7,79430,DB01235,Levodopa
,12942590,CL (clearance),"The t1/2 (half life time), CL (clearance) and volume of distribution (Vd) values calculated were 159 +/- 32 min, 51.7 +/- 5.1 1/h and 3.6 +/- 1.2 l/kg for Sinemet and 161 +/- 48 min, 58.7 +/- 8 l/h and 3.0 +/- 0.7 l/kg for Grifoparkin (NS).",[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),min,161,79431,DB01235,Levodopa
,12942590,CL (clearance),"The t1/2 (half life time), CL (clearance) and volume of distribution (Vd) values calculated were 159 +/- 32 min, 51.7 +/- 5.1 1/h and 3.6 +/- 1.2 l/kg for Sinemet and 161 +/- 48 min, 58.7 +/- 8 l/h and 3.0 +/- 0.7 l/kg for Grifoparkin (NS).",[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),[l] / [h],58.7,79432,DB01235,Levodopa
,12942590,volume of distribution (Vd),"The t1/2 (half life time), CL (clearance) and volume of distribution (Vd) values calculated were 159 +/- 32 min, 51.7 +/- 5.1 1/h and 3.6 +/- 1.2 l/kg for Sinemet and 161 +/- 48 min, 58.7 +/- 8 l/h and 3.0 +/- 0.7 l/kg for Grifoparkin (NS).",[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),[l] / [kg],3.6,79433,DB01235,Levodopa
,12942590,volume of distribution (Vd),"The t1/2 (half life time), CL (clearance) and volume of distribution (Vd) values calculated were 159 +/- 32 min, 51.7 +/- 5.1 1/h and 3.6 +/- 1.2 l/kg for Sinemet and 161 +/- 48 min, 58.7 +/- 8 l/h and 3.0 +/- 0.7 l/kg for Grifoparkin (NS).",[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),[l] / [kg],3.0,79434,DB01235,Levodopa
,10606836,overall clearance,"The overall clearance of tolcapone could be estimated with good precision (approximately 4. 5-5 l h-1 ), and none of the investigated covariates (e.g. sex, age, body weight) had any clinically significant influence on this parameter.",Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606836/),[l] / [h],4. 5-5,80316,DB01235,Levodopa
,10606836,volume of distribution,"The volume of distribution showed relatively high variability and was calculated to be approximately 30 l, leading to an estimated half-life in patients of approximately 5-8 h.",Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606836/),l,30,80317,DB01235,Levodopa
,10606836,half-life,"The volume of distribution showed relatively high variability and was calculated to be approximately 30 l, leading to an estimated half-life in patients of approximately 5-8 h.",Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606836/),h,5-8,80318,DB01235,Levodopa
,29345156,half-life,"It significantly decreases COMT activity, with half-life of COMT inhibition in human erythrocytes of 61.6 h and increases systemic exposure to L-Dopa.",Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson's disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29345156/),h,61.6,84649,DB01235,Levodopa
,6717507,cardiac index,"Peak hemodynamic responses occurred one hour after the ingestion of levodopa, with the mean (+/- S.E.M.) cardiac index increasing from 1.8 +/- 0.1 to 2.4 +/- 0.2 liters per minute per square meter of body-surface area (P less than 0.01) and systemic vascular resistance declining from 1905 +/- 112 to 1513 +/- 121 dyn X sec X cm-5 (P less than 0.01).",Beneficial hemodynamic effects of oral levodopa in heart failure. Relation to the generation of dopamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6717507/),[l] / [meter·min·square],1.8,87296,DB01235,Levodopa
,6717507,cardiac index,"Peak hemodynamic responses occurred one hour after the ingestion of levodopa, with the mean (+/- S.E.M.) cardiac index increasing from 1.8 +/- 0.1 to 2.4 +/- 0.2 liters per minute per square meter of body-surface area (P less than 0.01) and systemic vascular resistance declining from 1905 +/- 112 to 1513 +/- 121 dyn X sec X cm-5 (P less than 0.01).",Beneficial hemodynamic effects of oral levodopa in heart failure. Relation to the generation of dopamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6717507/),[l] / [meter·min·square],2.4,87297,DB01235,Levodopa
,6717507,systemic vascular resistance,"Peak hemodynamic responses occurred one hour after the ingestion of levodopa, with the mean (+/- S.E.M.) cardiac index increasing from 1.8 +/- 0.1 to 2.4 +/- 0.2 liters per minute per square meter of body-surface area (P less than 0.01) and systemic vascular resistance declining from 1905 +/- 112 to 1513 +/- 121 dyn X sec X cm-5 (P less than 0.01).",Beneficial hemodynamic effects of oral levodopa in heart failure. Relation to the generation of dopamine. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6717507/),[dyn·s] / [(cm)^5],1905,87298,DB01235,Levodopa
,6717507,systemic vascular resistance,"Peak hemodynamic responses occurred one hour after the ingestion of levodopa, with the mean (+/- S.E.M.) cardiac index increasing from 1.8 +/- 0.1 to 2.4 +/- 0.2 liters per minute per square meter of body-surface area (P less than 0.01) and systemic vascular resistance declining from 1905 +/- 112 to 1513 +/- 121 dyn X sec X cm-5 (P less than 0.01).",Beneficial hemodynamic effects of oral levodopa in heart failure. Relation to the generation of dopamine. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6717507/),[dyn·s] / [(cm)^5],1513,87299,DB01235,Levodopa
,6717507,peak level,Plasma concentrations of dopamine rose to a peak level of 34 +/- 5 ng per milliliter one hour after drug ingestion and decreased toward base line over the ensuing five hours.,Beneficial hemodynamic effects of oral levodopa in heart failure. Relation to the generation of dopamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6717507/),[ng] / [milliliter],34,87300,DB01235,Levodopa
,11432539,CURSsigma,"At baseline (day 1, before the first levodopa dose), CURSsigma averaged 40 +/- 10 points.",Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432539/),points,40,92445,DB01235,Levodopa
,11432539,CURSsigma,CURSsigma declined to 20 +/- 9 points.,Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432539/),points,20,92446,DB01235,Levodopa
,11432539,50% effective concentration (EC50),The population mean of the 50% effective concentration (EC50) of levodopa was 1350 microg/L with an standard error of the population parameter estimate of 18%: adding tolcapone treatment as a covariate did not significantly change the population fit.,Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432539/),[μg] / [l],1350,92447,DB01235,Levodopa
,30203852,flow rate,"The chromatographic analysis was achieved on a Shimadzu LC 20A HPLC system equipped with a Zorbax Eclipse XDB C18 column and an isocratic mobile phase consisting of 20 mm KH2 PO4 (pH 2.5) and methanol (95:5, v/v) run at a flow rate of 1 mL/min.",A new validated HPLC method for the determination of levodopa: Application to study the impact of ketogenic diet on the pharmacokinetics of levodopa in Parkinson's participants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30203852/),[ml] / [min],1,93057,DB01235,Levodopa
,14646613,tmax,Plasma levodopa tmax was significantly shorter with all three modes of administration of etilevodopa (mean of about 30 minutes) than with levodopa treatment (mean of 54 minutes).,"Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14646613/),min,30,93618,DB01235,Levodopa
,14646613,tmax,Plasma levodopa tmax was significantly shorter with all three modes of administration of etilevodopa (mean of about 30 minutes) than with levodopa treatment (mean of 54 minutes).,"Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14646613/),min,54,93619,DB01235,Levodopa
,14646613,Cmax,Mean levodopa Cmax was in the range 2.3 to 2.7 microg/mL for all treatments.,"Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14646613/),[μg] / [ml],2.3 to 2.7,93620,DB01235,Levodopa
,8012555,recoveries,"The intra- and inter-assay precision varied in the 2.4-6.9% and 3.2-9.1% ranges respectively, whereas the recoveries were close to 85% for L-DOPA and 3-OMD and 70% for DA and LDME.","Simultaneous determination of levodopa methyl ester, levodopa, 3-O-methyldopa and dopamine in plasma by high-performance liquid chromatography with electrochemical detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8012555/),%,85,98555,DB01235,Levodopa
,8012555,recoveries,"The intra- and inter-assay precision varied in the 2.4-6.9% and 3.2-9.1% ranges respectively, whereas the recoveries were close to 85% for L-DOPA and 3-OMD and 70% for DA and LDME.","Simultaneous determination of levodopa methyl ester, levodopa, 3-O-methyldopa and dopamine in plasma by high-performance liquid chromatography with electrochemical detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8012555/),%,70,98556,DB01235,Levodopa
,18248312,transit time,"Levodopa is only absorbed in the small intestine, where transit time is approximately 3 h and the plasma elimination half-life is short.",Irregular gastrointestinal drug absorption in Parkinson's disease. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18248312/),h,3,98632,DB01235,Levodopa
,25795100,Absolute bioavailability,Absolute bioavailability after 24 h transdermal delivery is 37 % of the applied rotigotine dose.,"An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25795100/),%,37,99596,DB01235,Levodopa
>,25795100,apparent volume of distribution,The drug shows a high apparent volume of distribution (>2500 L) and a total body clearance of 300-600 L/h.,"An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25795100/),l,2500,99597,DB01235,Levodopa
,25795100,total body clearance,The drug shows a high apparent volume of distribution (>2500 L) and a total body clearance of 300-600 L/h.,"An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25795100/),[l] / [h],300-600,99598,DB01235,Levodopa
,24433449,absorption,"The final model was a two compartment model with a transit compartment for absorption, first order elimination, bioavailability for LCIG (97%; confidence interval = 95% to 98%) relative to LC-oral, different first order transit absorption rate constants (LCIG = 9.2 h(-1) vs.",Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24433449/),%,97,101991,DB01235,Levodopa
,24433449,"first order elimination, bioavailability","The final model was a two compartment model with a transit compartment for absorption, first order elimination, bioavailability for LCIG (97%; confidence interval = 95% to 98%) relative to LC-oral, different first order transit absorption rate constants (LCIG = 9.2 h(-1) vs.",Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24433449/),%,97,101992,DB01235,Levodopa
,24433449,first order transit absorption rate constants,"The final model was a two compartment model with a transit compartment for absorption, first order elimination, bioavailability for LCIG (97%; confidence interval = 95% to 98%) relative to LC-oral, different first order transit absorption rate constants (LCIG = 9.2 h(-1) vs.",Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24433449/),1/[h],9.2,101993,DB01235,Levodopa
,24433449,mean absorption time,"LC-oral = 2.4 h(-1) ; corresponding mean absorption time of 7 min for LCIG vs. 25 min for LC-oral) and different residual (intra-subject) variability for LCIG (15% proportional error, 0.3 μg ml(-1) additive error) vs. LC-oral (29% proportional error, 0.59 μg ml(-1) additive error).",Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24433449/),min,7,101994,DB01235,Levodopa
,24433449,mean absorption time,"LC-oral = 2.4 h(-1) ; corresponding mean absorption time of 7 min for LCIG vs. 25 min for LC-oral) and different residual (intra-subject) variability for LCIG (15% proportional error, 0.3 μg ml(-1) additive error) vs. LC-oral (29% proportional error, 0.59 μg ml(-1) additive error).",Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24433449/),min,25,101995,DB01235,Levodopa
,24433449,oral clearance,"Estimated oral clearance and steady-state volume of distribution for levodopa were 24.8 l h(-1) and 131 l, respectively.",Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24433449/),[l] / [h],24.8,101996,DB01235,Levodopa
,24433449,steady-state volume of distribution,"Estimated oral clearance and steady-state volume of distribution for levodopa were 24.8 l h(-1) and 131 l, respectively.",Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24433449/),l,131,101997,DB01235,Levodopa
,22722022,maximal plasma concentration of L-DOPA (C(max)),The maximal plasma concentration of L-DOPA (C(max)) was 18.2 ± 3.8 nmol/ml and was achieved 1.6 ± 0.3 h after administration (t(max)).,L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22722022/),[nM] / [ml],18.2,103432,DB01235,Levodopa
,22722022,t(max),The maximal plasma concentration of L-DOPA (C(max)) was 18.2 ± 3.8 nmol/ml and was achieved 1.6 ± 0.3 h after administration (t(max)).,L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22722022/),h,1.6,103433,DB01235,Levodopa
,22722022,Half-life,Half-life was 58.8 ± 22.7 min.,L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22722022/),min,58.8,103434,DB01235,Levodopa
,14642830,t(max),"With a clinically therapeutic dosage of L-dopa/benserazide (20/5 mg/kg, p.o.), the t(max) of L-dopa was 30 min in plasma and 60-90 min in ECF of striatum.",Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14642830/),min,30,104250,DB01235,Levodopa
,14642830,t(max),"With a clinically therapeutic dosage of L-dopa/benserazide (20/5 mg/kg, p.o.), the t(max) of L-dopa was 30 min in plasma and 60-90 min in ECF of striatum.",Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14642830/),min,60-90,104251,DB01235,Levodopa
,14642830,C(max),"Mean C(max) was 20.3 microM in plasma and 442.9 nM in ECF of striatum, which is about 2.2% of that in plasma.",Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14642830/),μM,20.3,104252,DB01235,Levodopa
,14642830,C(max),"Mean C(max) was 20.3 microM in plasma and 442.9 nM in ECF of striatum, which is about 2.2% of that in plasma.",Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14642830/),nM,442.9,104253,DB01235,Levodopa
,18850046,C(max),"After 7 days of treatment, the levodopa AUC increased by 12.6% from day 1 (range: 114.2-150.7 microg.min/ml) to day 7 (range: 131.1-166.0 microg.min/ml) and C(max) increased by 9.6% (range: 1.90-2.86 microg/ml on day 1 and 2.12-3.13 microg/ml on day 7).",Evolution of the bioavailability and other pharmacokinetic parameters of levodopa (with carbidopa) in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18850046/),[μg] / [ml],1.90-2.86,105132,DB01235,Levodopa
,18850046,C(max),"After 7 days of treatment, the levodopa AUC increased by 12.6% from day 1 (range: 114.2-150.7 microg.min/ml) to day 7 (range: 131.1-166.0 microg.min/ml) and C(max) increased by 9.6% (range: 1.90-2.86 microg/ml on day 1 and 2.12-3.13 microg/ml on day 7).",Evolution of the bioavailability and other pharmacokinetic parameters of levodopa (with carbidopa) in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18850046/),[μg] / [ml],2.12-3.13,105133,DB01235,Levodopa
,18850046,C(max),"After 14 days of treatment, the increase in AUC was 17.0% (range: 119.6-160.1 microg.min/ml on day 1 and 142.9-172.7 microg.min/ml on day 14) and C(max) increased by 6.5% (range: 2.29-2.96 microg/ml on day 1 and 2.41-3.07 microg/ml on day 14).",Evolution of the bioavailability and other pharmacokinetic parameters of levodopa (with carbidopa) in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18850046/),[μg] / [ml],2.29-2.96,105134,DB01235,Levodopa
,18850046,C(max),"After 14 days of treatment, the increase in AUC was 17.0% (range: 119.6-160.1 microg.min/ml on day 1 and 142.9-172.7 microg.min/ml on day 14) and C(max) increased by 6.5% (range: 2.29-2.96 microg/ml on day 1 and 2.41-3.07 microg/ml on day 14).",Evolution of the bioavailability and other pharmacokinetic parameters of levodopa (with carbidopa) in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18850046/),[μg] / [ml],2.41-3.07,105135,DB01235,Levodopa
,25855267,Bioavailability,"Bioavailability of LD from ER CD-LD was 83.5%, 78.3%, and 58.8% relative to IR CD-LD, CR CD-LD, and CD-LD-entacapone, respectively.","Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25855267/),%,83.5,105136,DB01235,Levodopa
,25855267,Bioavailability,"Bioavailability of LD from ER CD-LD was 83.5%, 78.3%, and 58.8% relative to IR CD-LD, CR CD-LD, and CD-LD-entacapone, respectively.","Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25855267/),%,78.3,105137,DB01235,Levodopa
,25855267,Bioavailability,"Bioavailability of LD from ER CD-LD was 83.5%, 78.3%, and 58.8% relative to IR CD-LD, CR CD-LD, and CD-LD-entacapone, respectively.","Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25855267/),%,58.8,105138,DB01235,Levodopa
,22762460,FI,"FI for dose 2-5 was on average 1.26 for levodopa in LC-5, and 2.23 for dose 1-2 of LCE.",Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762460/),,1.26,105533,DB01235,Levodopa
,22762460,FI,"FI for dose 2-5 was on average 1.26 for levodopa in LC-5, and 2.23 for dose 1-2 of LCE.",Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762460/),,2.23,105534,DB01235,Levodopa
,31595429,bioavailability,Both the ODE and the SDE models estimated bioavailability to be approximately 75%.,Investigating Stochastic Differential Equations Modelling for Levodopa Infusion in Patients with Parkinson's Disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31595429/),%,75,111266,DB01235,Levodopa
,21297456,mean absorption time,"Estimated population parameter values were a mean absorption time of 28.5 minutes, a lag time of 2.9 minutes, and a bioavailability of 88%.",A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21297456/),min,28.5,112475,DB01235,Levodopa
,21297456,lag time,"Estimated population parameter values were a mean absorption time of 28.5 minutes, a lag time of 2.9 minutes, and a bioavailability of 88%.",A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21297456/),min,2.9,112476,DB01235,Levodopa
,21297456,bioavailability,"Estimated population parameter values were a mean absorption time of 28.5 minutes, a lag time of 2.9 minutes, and a bioavailability of 88%.",A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21297456/),%,88,112477,DB01235,Levodopa
,21297456,half-life of effect delay,"The pharmacodynamic model for motor ratings had the following population values: a half-life of effect delay of 21 minutes, a concentration at 50% effect of 1.55 mg/L, an Emax of 2.39 U on the treatment response scale, and a sigmoidicity of the Emax function of 11.6.",A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21297456/),min,21,112478,DB01235,Levodopa
,21297456,concentration at 50% effect,"The pharmacodynamic model for motor ratings had the following population values: a half-life of effect delay of 21 minutes, a concentration at 50% effect of 1.55 mg/L, an Emax of 2.39 U on the treatment response scale, and a sigmoidicity of the Emax function of 11.6.",A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21297456/),[mg] / [l],1.55,112479,DB01235,Levodopa
,21297456,Emax,"The pharmacodynamic model for motor ratings had the following population values: a half-life of effect delay of 21 minutes, a concentration at 50% effect of 1.55 mg/L, an Emax of 2.39 U on the treatment response scale, and a sigmoidicity of the Emax function of 11.6.",A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21297456/),u,2.39,112480,DB01235,Levodopa
,21297456,Emax,"The pharmacodynamic model for motor ratings had the following population values: a half-life of effect delay of 21 minutes, a concentration at 50% effect of 1.55 mg/L, an Emax of 2.39 U on the treatment response scale, and a sigmoidicity of the Emax function of 11.6.",A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21297456/),,11,112481,DB01235,Levodopa
,27713822,CL/F,"CL/F, Vd/F, and KA (95% confidence interval [CI]) were 4.96 (4.73-5.21) L/h, 166 (158-174) L, and 0.582 (0.335-0.829) h-1, respectively.",Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27713822/),[l] / [h],4.96,112515,DB01235,Levodopa
,27713822,Vd/F,"CL/F, Vd/F, and KA (95% confidence interval [CI]) were 4.96 (4.73-5.21) L/h, 166 (158-174) L, and 0.582 (0.335-0.829) h-1, respectively.",Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27713822/),l,166,112516,DB01235,Levodopa
,27713822,KA,"CL/F, Vd/F, and KA (95% confidence interval [CI]) were 4.96 (4.73-5.21) L/h, 166 (158-174) L, and 0.582 (0.335-0.829) h-1, respectively.",Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27713822/),1/[h],0.582,112517,DB01235,Levodopa
,11294372,volume of the central compartment (Vc),"The volume of the central compartment (Vc) and the volume of distribution at steady state (Vss) were 0.08+/-0.03 l/kg and 0.27+/-0.10 l/kg, respectively.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),[l] / [kg],0.08,113234,DB01235,Levodopa
,11294372,volume of distribution at steady state (Vss),"The volume of the central compartment (Vc) and the volume of distribution at steady state (Vss) were 0.08+/-0.03 l/kg and 0.27+/-0.10 l/kg, respectively.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),[l] / [kg],0.27,113235,DB01235,Levodopa
,11294372,Total plasma clearance (Cltot),Total plasma clearance (Cltot) averaged 11.7+/-1.9 ml/min kg(-1).,"Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),[min·ml] / [kg],11.7,113236,DB01235,Levodopa
,11294372,half-lives,"The half-lives for the distribution phase and for the rapid and terminal elimination phases (t1/2alpha, t1/2beta and t1/2gamma) were 0.05+/-0.01 h, 0.38+/-0.16 h and 2.40+/-1.70 h, respectively.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),h,0.05,113237,DB01235,Levodopa
,11294372,half-lives,"The half-lives for the distribution phase and for the rapid and terminal elimination phases (t1/2alpha, t1/2beta and t1/2gamma) were 0.05+/-0.01 h, 0.38+/-0.16 h and 2.40+/-1.70 h, respectively.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),h,0.38,113238,DB01235,Levodopa
,11294372,t1/2alpha,"The half-lives for the distribution phase and for the rapid and terminal elimination phases (t1/2alpha, t1/2beta and t1/2gamma) were 0.05+/-0.01 h, 0.38+/-0.16 h and 2.40+/-1.70 h, respectively.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),h,0.05,113239,DB01235,Levodopa
,11294372,t1/2beta,"The half-lives for the distribution phase and for the rapid and terminal elimination phases (t1/2alpha, t1/2beta and t1/2gamma) were 0.05+/-0.01 h, 0.38+/-0.16 h and 2.40+/-1.70 h, respectively.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),h,0.05,113240,DB01235,Levodopa
,11294372,t1/2beta,"The half-lives for the distribution phase and for the rapid and terminal elimination phases (t1/2alpha, t1/2beta and t1/2gamma) were 0.05+/-0.01 h, 0.38+/-0.16 h and 2.40+/-1.70 h, respectively.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),h,0.38,113241,DB01235,Levodopa
,11294372,t1/2gamma,"The half-lives for the distribution phase and for the rapid and terminal elimination phases (t1/2alpha, t1/2beta and t1/2gamma) were 0.05+/-0.01 h, 0.38+/-0.16 h and 2.40+/-1.70 h, respectively.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),h,2.40,113242,DB01235,Levodopa
,11294372,total,"The terminal elimination phase accounted for only 9% of the total area under the plasma concentration-time curve (AUC), which was 409 +/- 98 ng h/ml after the i.v. dose.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),[h·ng] / [ml],409,113243,DB01235,Levodopa
,11294372,area under the plasma concentration-time curve (AUC),"The terminal elimination phase accounted for only 9% of the total area under the plasma concentration-time curve (AUC), which was 409 +/- 98 ng h/ml after the i.v. dose.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),[h·ng] / [ml],409,113244,DB01235,Levodopa
,11294372,time to reach the peak concentration (tmax),"Oral entacapone was absorbed rapidly with a time to reach the peak concentration (tmax) of 0.9+/-0.4 h, a maximum concentration (Cmax) of 457+/-334 ng/ml and an AUC of 497+/-118 ng h/ml.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),h,0.9,113245,DB01235,Levodopa
,11294372,maximum concentration (Cmax),"Oral entacapone was absorbed rapidly with a time to reach the peak concentration (tmax) of 0.9+/-0.4 h, a maximum concentration (Cmax) of 457+/-334 ng/ml and an AUC of 497+/-118 ng h/ml.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),[ng] / [ml],457,113246,DB01235,Levodopa
,11294372,AUC,"Oral entacapone was absorbed rapidly with a time to reach the peak concentration (tmax) of 0.9+/-0.4 h, a maximum concentration (Cmax) of 457+/-334 ng/ml and an AUC of 497+/-118 ng h/ml.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),[h·ng] / [ml],497,113247,DB01235,Levodopa
,11294372,recovery,"During the 48 h after dosing, the recovery of free and conjugated unchanged 13C-entacapone in urine was 38.1+/-7.2% of the i.v. dose and the recovery of free and conjugated unchanged entacapone 13.3+/-3.9% of the oral dose.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),%,38.1,113248,DB01235,Levodopa
,11294372,recovery,"During the 48 h after dosing, the recovery of free and conjugated unchanged 13C-entacapone in urine was 38.1+/-7.2% of the i.v. dose and the recovery of free and conjugated unchanged entacapone 13.3+/-3.9% of the oral dose.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),%,13.3,113249,DB01235,Levodopa
,11294372,bioavailability,The bioavailability of oral entacapone was 25% based on the AUC values and 35% based on urinary excretion.,"Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),%,25,113250,DB01235,Levodopa
,11294372,bioavailability,The bioavailability of oral entacapone was 25% based on the AUC values and 35% based on urinary excretion.,"Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),%,35,113251,DB01235,Levodopa
≤,28322896,time to reach the maximum plasma concentration,Opicapone was quickly absorbed (time to reach the maximum plasma concentration≤2h) in both dosage regimens and the extent of systemic exposure to opicapone increased approximately in a dose-proportional manner after single-dosing within the studied dose range (30-90mg/kg).,"Pharmacokinetics of opicapone, a third-generation COMT inhibitor, after single and multiple oral administration: A comparative study in the rat. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28322896/),h,2,115003,DB01235,Levodopa
,28322896,plasma elimination half-life,Opicapone and BIA 9-1079 showed a relatively short plasma elimination half-life (1.58-4.50h) and a small systemic accumulation after multiple-dosing.,"Pharmacokinetics of opicapone, a third-generation COMT inhibitor, after single and multiple oral administration: A comparative study in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28322896/),h,1.58-4.50,115004,DB01235,Levodopa
,2611767,peak levels,"After loading of bromocriptine alone, we found mean peak levels at 60 min (1.42 ng/ml) and at 90 min (1.82 ng/ml).",The influence of levodopa in the pharmacokinetics of bromocriptine in Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611767/),[ng] / [ml],1.42,115958,DB01235,Levodopa
,2611767,peak levels,"After loading of bromocriptine alone, we found mean peak levels at 60 min (1.42 ng/ml) and at 90 min (1.82 ng/ml).",The influence of levodopa in the pharmacokinetics of bromocriptine in Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611767/),[ng] / [ml],1.82,115959,DB01235,Levodopa
,8813223,time to peak plasma concentrations,"The mean time to peak plasma concentrations was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 micrograms/ml/h with Sinemet and 2,330 micrograms/ml/h with Atamet.",Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8813223/),min,49,117571,DB01235,Levodopa
,8813223,time to peak plasma concentrations,"The mean time to peak plasma concentrations was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 micrograms/ml/h with Sinemet and 2,330 micrograms/ml/h with Atamet.",Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8813223/),min,47,117572,DB01235,Levodopa
,8813223,peak plasma concentration,"The mean time to peak plasma concentrations was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 micrograms/ml/h with Sinemet and 2,330 micrograms/ml/h with Atamet.",Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8813223/),[ng] / [ml],"1,273",117573,DB01235,Levodopa
,8813223,peak plasma concentration,"The mean time to peak plasma concentrations was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 micrograms/ml/h with Sinemet and 2,330 micrograms/ml/h with Atamet.",Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8813223/),[ng] / [ml],"1,153",117574,DB01235,Levodopa
,8813223,area under the curve,"The mean time to peak plasma concentrations was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 micrograms/ml/h with Sinemet and 2,330 micrograms/ml/h with Atamet.",Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8813223/),[μg] / [h·ml],"2,295",117575,DB01235,Levodopa
,8813223,area under the curve,"The mean time to peak plasma concentrations was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 micrograms/ml/h with Sinemet and 2,330 micrograms/ml/h with Atamet.",Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8813223/),[μg] / [h·ml],"2,330",117576,DB01235,Levodopa
,26861609,t1/2,"Pharmacokinetic studies showed elimination half-life of l-DOPA in the plasma after DopAmide treatment of t1/2 = 4.1 h, significantly longer than t1/2 = 2.9 h after treatment with l-DOPA, consistent with the 6-OHDA results.","DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26861609/),h,4.1,117581,DB01235,Levodopa
,26861609,t1/2,"Pharmacokinetic studies showed elimination half-life of l-DOPA in the plasma after DopAmide treatment of t1/2 = 4.1 h, significantly longer than t1/2 = 2.9 h after treatment with l-DOPA, consistent with the 6-OHDA results.","DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26861609/),h,2.9,117582,DB01235,Levodopa
,10510160,"AUC(0,tau)","The mean AUC(0,tau) and Cmax values at baseline were 0.39 microg ml-1 h and 0. 14 microg ml-1, respectively.",COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510160/),[h·μg] / [ml],0.39,121517,DB01235,Levodopa
,10510160,Cmax,"The mean AUC(0,tau) and Cmax values at baseline were 0.39 microg ml-1 h and 0. 14 microg ml-1, respectively.",COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510160/),[μg] / [ml],0. 14,121518,DB01235,Levodopa
,10510160,"AUC(0,tau)","During tolcapone treatment these values were on average 0.35 microg ml-1 h (AUC(0,tau), week 1-2), 0. 34 microg ml-1 h (AUC(0,tau), week 6 and 0.13 microg ml-1 (Cmax, weeks 1-2 and 6).",COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510160/),[h·μg] / [ml],0.35,121519,DB01235,Levodopa
,10510160,"AUC(0,tau)","During tolcapone treatment these values were on average 0.35 microg ml-1 h (AUC(0,tau), week 1-2), 0. 34 microg ml-1 h (AUC(0,tau), week 6 and 0.13 microg ml-1 (Cmax, weeks 1-2 and 6).",COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510160/),[h·μg] / [ml],0. 34,121520,DB01235,Levodopa
,10510160,Cmax,"During tolcapone treatment these values were on average 0.35 microg ml-1 h (AUC(0,tau), week 1-2), 0. 34 microg ml-1 h (AUC(0,tau), week 6 and 0.13 microg ml-1 (Cmax, weeks 1-2 and 6).",COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510160/),[μg] / [ml],0.13,121521,DB01235,Levodopa
,10510160,tmax,tmax remained unchanged (approx. 2 h).,COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510160/),h,2,121522,DB01235,Levodopa
,7479562,AUC0-->3,"The AUC0-->3 values for the non-protein bound L-DOPA did not differ significantly between the dialysis (141.3 +/- 16.0 nmol.h/ml) and traditional whole blood sampling (145.3 +/- 18.7 nmol.h/ml), confirming that microdialysis combined with accurate calibration is a reliable technique for studying the kinetics of drugs in vivo in different tissues.",Quantitative microdialysis for studying the in vivo L-DOPA kinetics in blood and skeletal muscle of the dog. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479562/),[h·nM] / [ml],141.3,123322,DB01235,Levodopa
,7479562,AUC0-->3,"The AUC0-->3 values for the non-protein bound L-DOPA did not differ significantly between the dialysis (141.3 +/- 16.0 nmol.h/ml) and traditional whole blood sampling (145.3 +/- 18.7 nmol.h/ml), confirming that microdialysis combined with accurate calibration is a reliable technique for studying the kinetics of drugs in vivo in different tissues.",Quantitative microdialysis for studying the in vivo L-DOPA kinetics in blood and skeletal muscle of the dog. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479562/),[h·nM] / [ml],145.3,123323,DB01235,Levodopa
,9579293,area under the curve,The area under the curve was 1599 +/- 615 ng.ml-1 h. (levodopa + saline) and 1821 +/- 625 ng.ml-1.h (levodopa + apomorphine).,Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),[h·ng] / [ml],1599,127166,DB01235,Levodopa
,9579293,area under the curve,The area under the curve was 1599 +/- 615 ng.ml-1 h. (levodopa + saline) and 1821 +/- 625 ng.ml-1.h (levodopa + apomorphine).,Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),[h·ng] / [ml],1821,127167,DB01235,Levodopa
,9579293,Cmax,Cmax was 1094 +/- 476 ng.ml-1 (levodopa + saline) and 1129 +/- 435 ng.ml-1 (levodopa + apomorphine).,Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),[ng] / [ml],1094,127168,DB01235,Levodopa
,9579293,Cmax,Cmax was 1094 +/- 476 ng.ml-1 (levodopa + saline) and 1129 +/- 435 ng.ml-1 (levodopa + apomorphine).,Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),[ng] / [ml],1129,127169,DB01235,Levodopa
,9579293,EC50,"Estimates of the EC50 of levodopa decreased significantly from 430 +/- 163 ng.ml-1 (levodopa + saline) to 315 +/- 123 ng+ml-1 (levodopa + apomorphine) (95% confidence interval [CI] 0.51 -0.98, point estimator 0.75).",Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),[ng] / [ml],430,127170,DB01235,Levodopa
,9579293,EC50,"Estimates of the EC50 of levodopa decreased significantly from 430 +/- 163 ng.ml-1 (levodopa + saline) to 315 +/- 123 ng+ml-1 (levodopa + apomorphine) (95% confidence interval [CI] 0.51 -0.98, point estimator 0.75).",Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),1/[ng+ml],315,127171,DB01235,Levodopa
,9579293,duration of the motor response,"The mean duration of the motor response rose from 1.9 +/- 0.5 h (levodopa + saline) to 3.0 +/- 0.9 h (levodopa + apomorphine (95% CI 1.23 to 2.06, point estimator 1.60).",Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),h,1.9,127172,DB01235,Levodopa
,9579293,duration of the motor response,"The mean duration of the motor response rose from 1.9 +/- 0.5 h (levodopa + saline) to 3.0 +/- 0.9 h (levodopa + apomorphine (95% CI 1.23 to 2.06, point estimator 1.60).",Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),h,3.0,127173,DB01235,Levodopa
,2089102,Ki,Ro 40-7592 was found to inhibit COMT in a competitive fashion both in the CNS and in the periphery (Ki for the liver enzyme = 30 nM).,Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2089102/),nM,30,131877,DB01235,Levodopa
,2076722,half-life,The disequilibrium half-life for development of effect after oral administration was calculated to be about 30 min.,Pharmacokinetics and effects of levodopa in advanced Parkinson's disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076722/),min,30,133317,DB01235,Levodopa
,26366963,peak plasma LD concentration (Cmax),"Levodopa bioavailability was markedly lower after Mucuna administration compared with LD standard formulations: in patient 1, peak plasma LD concentration (Cmax) decreased from 2.0 to 1.0 mg/L and the area under the plasma concentration time curve from 137 to 33.6 mg/L per minute; in patient 2, Cmax was 0.7 mg/L after LD/benserazide and nearly undetectable after Mucuna.",Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26366963/),[mg] / [l],2.0,135959,DB01235,Levodopa
,26366963,peak plasma LD concentration (Cmax),"Levodopa bioavailability was markedly lower after Mucuna administration compared with LD standard formulations: in patient 1, peak plasma LD concentration (Cmax) decreased from 2.0 to 1.0 mg/L and the area under the plasma concentration time curve from 137 to 33.6 mg/L per minute; in patient 2, Cmax was 0.7 mg/L after LD/benserazide and nearly undetectable after Mucuna.",Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26366963/),[mg] / [l],1.0,135960,DB01235,Levodopa
,26366963,area under the plasma concentration time curve,"Levodopa bioavailability was markedly lower after Mucuna administration compared with LD standard formulations: in patient 1, peak plasma LD concentration (Cmax) decreased from 2.0 to 1.0 mg/L and the area under the plasma concentration time curve from 137 to 33.6 mg/L per minute; in patient 2, Cmax was 0.7 mg/L after LD/benserazide and nearly undetectable after Mucuna.",Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26366963/),[mg] / [l·min],137,135961,DB01235,Levodopa
,26366963,area under the plasma concentration time curve,"Levodopa bioavailability was markedly lower after Mucuna administration compared with LD standard formulations: in patient 1, peak plasma LD concentration (Cmax) decreased from 2.0 to 1.0 mg/L and the area under the plasma concentration time curve from 137 to 33.6 mg/L per minute; in patient 2, Cmax was 0.7 mg/L after LD/benserazide and nearly undetectable after Mucuna.",Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26366963/),[mg] / [l·min],33.6,135962,DB01235,Levodopa
,26366963,Cmax,"Levodopa bioavailability was markedly lower after Mucuna administration compared with LD standard formulations: in patient 1, peak plasma LD concentration (Cmax) decreased from 2.0 to 1.0 mg/L and the area under the plasma concentration time curve from 137 to 33.6 mg/L per minute; in patient 2, Cmax was 0.7 mg/L after LD/benserazide and nearly undetectable after Mucuna.",Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26366963/),[mg] / [l],0.7,135963,DB01235,Levodopa
,12865145,steady-state levodopa concentrations,"At higher doses (target steady-state levodopa concentrations of 2,169 and 1,200 ng/ml), treatment-naive volunteers had unacceptably frequent side effects.",Rapid intravenous loading of levodopa for human research: clinical results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12865145/),[ng] / [ml],"2,169",136647,DB01235,Levodopa
,12865145,steady-state levodopa concentrations,"At higher doses (target steady-state levodopa concentrations of 2,169 and 1,200 ng/ml), treatment-naive volunteers had unacceptably frequent side effects.",Rapid intravenous loading of levodopa for human research: clinical results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12865145/),[ng] / [ml],"1,200",136648,DB01235,Levodopa
,12865145,steady-state concentration,"The final infusion protocol, with a target steady-state concentration of 600 ng/ml, was well-tolerated (mild nausea in 11% of subjects was the only side effect occurring significantly more than in single-blind saline infusions), produced the desired plasma levodopa concentration (612+/-187 ng/ml, mean+/-S.D.), and produced statistically significant antiparkinsonian benefit (16% mean reduction in a standard rating of parkinsonian motor signs, P<0.0005).",Rapid intravenous loading of levodopa for human research: clinical results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12865145/),[ng] / [ml],600,136649,DB01235,Levodopa
,9260033,peak plasma concentration (Cmax),The mean peak plasma concentration (Cmax) is approximately 2 micrograms/L and the time to reach the peak is under an hour.,Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260033/),[μg] / [l],2,136781,DB01235,Levodopa
under,9260033,time to reach the peak,The mean peak plasma concentration (Cmax) is approximately 2 micrograms/L and the time to reach the peak is under an hour.,Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260033/),h,an,136782,DB01235,Levodopa
,9260033,absolute bioavailability,The absolute bioavailability of selegiline is approximately 10%.,Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260033/),%,10,136783,DB01235,Levodopa
,9260033,apparent volume of distribution,It has an apparent volume of distribution of 1854 L.,Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260033/),l,1854,136784,DB01235,Levodopa
,9260033,oral clearance,"The oral clearance of selegiline (59 L/min) is many fold higher than the liver blood flow (1.5 L/min), indicating that extrahepatic processes are involved in the elimination of selegiline.",Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260033/),[l] / [min],59,136785,DB01235,Levodopa
,9260033,oral clearance,"The oral clearance of selegiline (59 L/min) is many fold higher than the liver blood flow (1.5 L/min), indicating that extrahepatic processes are involved in the elimination of selegiline.",Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260033/),[l] / [min],1.5,136786,DB01235,Levodopa
,9260033,elimination half-life,The elimination half-life of selegiline is about 1.5 hours.,Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260033/),h,1.5,136787,DB01235,Levodopa
,32010367,Bioavailability,"Bioavailability of the drug - nasal drops were 244.4% compared with the drug ""Madopar 125"".",Pharmacokinetics of Nanosomal Form of Levodopa in Intranasal Administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32010367/),%,244.4,138331,DB01235,Levodopa
,10552081,half-life,The fast component of the decay accounted for 40%-50% of the radioactivity and had a half-life of about 5 min.,The time course of metabolites in human plasma after 6-[(18)F]fluoro-l-m-tyrosine administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10552081/),min,5,138434,DB01235,Levodopa
,10552081,half-life,The slow component of the decay had a half-life of about 6 h in the subjects not taking carbidopa and 20 h in the patients taking carbidopa.,The time course of metabolites in human plasma after 6-[(18)F]fluoro-l-m-tyrosine administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10552081/),h,6,138435,DB01235,Levodopa
,10552081,half-life,The slow component of the decay had a half-life of about 6 h in the subjects not taking carbidopa and 20 h in the patients taking carbidopa.,The time course of metabolites in human plasma after 6-[(18)F]fluoro-l-m-tyrosine administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10552081/),h,20,138436,DB01235,Levodopa
,8730980,total AUC,Benzhexol administration did not affect the total AUC of levodopa (7.30 +/- 1.09 vs 7.19 +/- 1.26 micrograms ml-1 h; means +/- s.d.).,The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8730980/),[h·μg] / [ml],7.30,140754,DB01235,Levodopa
,8730980,total AUC,Benzhexol administration did not affect the total AUC of levodopa (7.30 +/- 1.09 vs 7.19 +/- 1.26 micrograms ml-1 h; means +/- s.d.).,The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8730980/),[h·μg] / [ml],7.19,140755,DB01235,Levodopa
,8730980,total AUC,The total AUC of paracetamol was not affected by benzhexol administration (39.4 +/- 8.2 vs 40.0 +/- 8.9 micrograms ml-1 h; mean +/- s.d.) 4.,The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8730980/),[h·μg] / [ml],39.4,140756,DB01235,Levodopa
,8730980,total AUC,The total AUC of paracetamol was not affected by benzhexol administration (39.4 +/- 8.2 vs 40.0 +/- 8.9 micrograms ml-1 h; mean +/- s.d.) 4.,The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8730980/),[h·μg] / [ml],40.0,140757,DB01235,Levodopa
,3427559,Time to peak plasma levodopa concentration,"Time to peak plasma levodopa concentration increased threefold (from 45 +/- 23 to 134 +/- 76 min, p less than 0.001), when levodopa was administered after meals.",Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427559/),min,45,146617,DB01235,Levodopa
,3427559,Time to peak plasma levodopa concentration,"Time to peak plasma levodopa concentration increased threefold (from 45 +/- 23 to 134 +/- 76 min, p less than 0.001), when levodopa was administered after meals.",Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427559/),min,134,146618,DB01235,Levodopa
,25649051,Maximum COMT inhibition (Emax),Maximum COMT inhibition (Emax) ranged from 52% (5 mg OPC) to 80% (30 mg OPC).,"Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25649051/),%,52,147219,DB01235,Levodopa
,25649051,Maximum COMT inhibition (Emax),Maximum COMT inhibition (Emax) ranged from 52% (5 mg OPC) to 80% (30 mg OPC).,"Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25649051/),%,80,147220,DB01235,Levodopa
,29478239,Maximum plasma concentrations (Cmax),Maximum plasma concentrations (Cmax) of PF-06669571 were reached 3.35 and 3.19 h post-dose on day 1 and day 7.,"A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson's Disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29478239/),h,3.35,149136,DB01235,Levodopa
,29478239,Maximum plasma concentrations (Cmax),Maximum plasma concentrations (Cmax) of PF-06669571 were reached 3.35 and 3.19 h post-dose on day 1 and day 7.,"A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson's Disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29478239/),h,3.19,149137,DB01235,Levodopa
,29478239,Cmax,"Geometric mean Cmax and area under the plasma concentration-time profile from time 0 to 24 h post-dose on day 7 were 92.51 ng/mL and 1626 ng·h/mL, respectively.","A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson's Disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29478239/),[ng] / [ml],92.51,149138,DB01235,Levodopa
,29478239,area under the plasma concentration-time profile from time 0 to 24 h,"Geometric mean Cmax and area under the plasma concentration-time profile from time 0 to 24 h post-dose on day 7 were 92.51 ng/mL and 1626 ng·h/mL, respectively.","A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson's Disease. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29478239/),[h·ng] / [ml],1626,149139,DB01235,Levodopa
,2920496,peak levodopa levels,When levodopa was taken with ferrous sulfate there was a 55% decrease in peak levodopa levels (3.6 +/- 2.6 vs 1.6 +/- 0.82 nmol/ml; p less than 0.05) and a 51% decrease in AUC (257 +/- 133 vs 125 +/- 51 nmol.min/ml; p less than 0.01).,Ferrous sulfate reduces levodopa bioavailability: chelation as a possible mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920496/),[nM] / [ml],3.6,149240,DB01235,Levodopa
,2920496,peak levodopa levels,When levodopa was taken with ferrous sulfate there was a 55% decrease in peak levodopa levels (3.6 +/- 2.6 vs 1.6 +/- 0.82 nmol/ml; p less than 0.05) and a 51% decrease in AUC (257 +/- 133 vs 125 +/- 51 nmol.min/ml; p less than 0.01).,Ferrous sulfate reduces levodopa bioavailability: chelation as a possible mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920496/),[nM] / [ml],1.6,149241,DB01235,Levodopa
,2920496,AUC,When levodopa was taken with ferrous sulfate there was a 55% decrease in peak levodopa levels (3.6 +/- 2.6 vs 1.6 +/- 0.82 nmol/ml; p less than 0.05) and a 51% decrease in AUC (257 +/- 133 vs 125 +/- 51 nmol.min/ml; p less than 0.01).,Ferrous sulfate reduces levodopa bioavailability: chelation as a possible mechanism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920496/),[min·nM] / [ml],257,149242,DB01235,Levodopa
,2920496,AUC,When levodopa was taken with ferrous sulfate there was a 55% decrease in peak levodopa levels (3.6 +/- 2.6 vs 1.6 +/- 0.82 nmol/ml; p less than 0.05) and a 51% decrease in AUC (257 +/- 133 vs 125 +/- 51 nmol.min/ml; p less than 0.01).,Ferrous sulfate reduces levodopa bioavailability: chelation as a possible mechanism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920496/),[min·nM] / [ml],125,149243,DB01235,Levodopa
,1974290,t 1/2 alpha,"By the i.v. route, elimination followed apparent first order kinetics and was biphasic with a t 1/2 alpha of 7 min and terminal half-life of 67 min.","Pharmacokinetics, bioavailability, metabolism, tissue distribution and urinary excretion of gamma-L-glutamyl-L-dopa in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974290/),min,7,150493,DB01235,Levodopa
,1974290,terminal half-life,"By the i.v. route, elimination followed apparent first order kinetics and was biphasic with a t 1/2 alpha of 7 min and terminal half-life of 67 min.","Pharmacokinetics, bioavailability, metabolism, tissue distribution and urinary excretion of gamma-L-glutamyl-L-dopa in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974290/),min,67,150494,DB01235,Levodopa
,1974290,t 1/2 ab,"After i.p. administration absorption was rapid (t 1/2 ab 6 min), elimination was monophasic with a terminal half-life almost identical following i.v. dosing (65 min), and bioavailability was 40%.","Pharmacokinetics, bioavailability, metabolism, tissue distribution and urinary excretion of gamma-L-glutamyl-L-dopa in the rat. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974290/),min,6,150495,DB01235,Levodopa
,1974290,terminal half-life,"After i.p. administration absorption was rapid (t 1/2 ab 6 min), elimination was monophasic with a terminal half-life almost identical following i.v. dosing (65 min), and bioavailability was 40%.","Pharmacokinetics, bioavailability, metabolism, tissue distribution and urinary excretion of gamma-L-glutamyl-L-dopa in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974290/),min,65,150496,DB01235,Levodopa
,1974290,bioavailability,"After i.p. administration absorption was rapid (t 1/2 ab 6 min), elimination was monophasic with a terminal half-life almost identical following i.v. dosing (65 min), and bioavailability was 40%.","Pharmacokinetics, bioavailability, metabolism, tissue distribution and urinary excretion of gamma-L-glutamyl-L-dopa in the rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974290/),%,40,150497,DB01235,Levodopa
,19412946,area-under-the-concentration-curve,"PK analysis revealed the anticipated near-equivalent mean L-dopa area-under-the-concentration-curve values (639,490 ng min/mL for two doses of CLE, and 662,577 for CL-CR, P = 0.86).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),[min·ng] / [ml],"639,490",150783,DB01235,Levodopa
,19412946,area-under-the-concentration-curve,"PK analysis revealed the anticipated near-equivalent mean L-dopa area-under-the-concentration-curve values (639,490 ng min/mL for two doses of CLE, and 662,577 for CL-CR, P = 0.86).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),,"662,577",150784,DB01235,Levodopa
,19412946,maximal concentration,"The mean maximal concentration for the first CLE dose was 1,926 +/- 760 ng/mL and for CL-CR, 1,840 +/- 889 (P = 0.33).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),[ng] / [ml],"1,926",150785,DB01235,Levodopa
,19412946,CL-CR,"The mean maximal concentration for the first CLE dose was 1,926 +/- 760 ng/mL and for CL-CR, 1,840 +/- 889 (P = 0.33).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),,"1,840",150786,DB01235,Levodopa
,19412946,CL-CR,"During the PK studies, the mean time that L-dopa concentration was > or =1,000 ng/mL for CLE was 291 +/- 88 minutes and for CL-CR, 306 +/- 86 (P = 0.33).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),,306,150787,DB01235,Levodopa
,19412946,percent-time,"The mean percent-time in ""off"" state was 18% for CLE and 28% for CL-CR (P = 0.017), ""on state without dyskinesia"" was 64% for CLE and 65% for CL-CR (P = 0.803), and ""on state with nontroublesome dyskinesia"" was 18% for CLE and 7% for CL-CR (P = 0.03).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),%,18,150788,DB01235,Levodopa
,19412946,percent-time,"The mean percent-time in ""off"" state was 18% for CLE and 28% for CL-CR (P = 0.017), ""on state without dyskinesia"" was 64% for CLE and 65% for CL-CR (P = 0.803), and ""on state with nontroublesome dyskinesia"" was 18% for CLE and 7% for CL-CR (P = 0.03).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),%,28,150789,DB01235,Levodopa
,19412946,percent-time,"The mean percent-time in ""off"" state was 18% for CLE and 28% for CL-CR (P = 0.017), ""on state without dyskinesia"" was 64% for CLE and 65% for CL-CR (P = 0.803), and ""on state with nontroublesome dyskinesia"" was 18% for CLE and 7% for CL-CR (P = 0.03).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),%,64,150790,DB01235,Levodopa
,19412946,percent-time,"The mean percent-time in ""off"" state was 18% for CLE and 28% for CL-CR (P = 0.017), ""on state without dyskinesia"" was 64% for CLE and 65% for CL-CR (P = 0.803), and ""on state with nontroublesome dyskinesia"" was 18% for CLE and 7% for CL-CR (P = 0.03).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),%,65,150791,DB01235,Levodopa
,19412946,percent-time,"The mean percent-time in ""off"" state was 18% for CLE and 28% for CL-CR (P = 0.017), ""on state without dyskinesia"" was 64% for CLE and 65% for CL-CR (P = 0.803), and ""on state with nontroublesome dyskinesia"" was 18% for CLE and 7% for CL-CR (P = 0.03).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),%,7,150792,DB01235,Levodopa
,1761075,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) of levodopa was significantly greater in the older group (547 versus 428 mumol.l-1.min in Group B), coupled with a reduced apparent oral clearance (8.1 versus 10.7 ml.min-1.kg-1) and a longer plasma elimination half-life (67.6 versus 54.6 min).",Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761075/),[min·μM] / [l],547,150795,DB01235,Levodopa
,1761075,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) of levodopa was significantly greater in the older group (547 versus 428 mumol.l-1.min in Group B), coupled with a reduced apparent oral clearance (8.1 versus 10.7 ml.min-1.kg-1) and a longer plasma elimination half-life (67.6 versus 54.6 min).",Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761075/),[min·μM] / [l],428,150796,DB01235,Levodopa
,1761075,apparent oral clearance,"The area under the plasma concentration-time curve (AUC) of levodopa was significantly greater in the older group (547 versus 428 mumol.l-1.min in Group B), coupled with a reduced apparent oral clearance (8.1 versus 10.7 ml.min-1.kg-1) and a longer plasma elimination half-life (67.6 versus 54.6 min).",Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761075/),[ml] / [kg·min],8.1,150797,DB01235,Levodopa
,1761075,apparent oral clearance,"The area under the plasma concentration-time curve (AUC) of levodopa was significantly greater in the older group (547 versus 428 mumol.l-1.min in Group B), coupled with a reduced apparent oral clearance (8.1 versus 10.7 ml.min-1.kg-1) and a longer plasma elimination half-life (67.6 versus 54.6 min).",Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761075/),[ml] / [kg·min],10.7,150798,DB01235,Levodopa
,1761075,plasma elimination half-life,"The area under the plasma concentration-time curve (AUC) of levodopa was significantly greater in the older group (547 versus 428 mumol.l-1.min in Group B), coupled with a reduced apparent oral clearance (8.1 versus 10.7 ml.min-1.kg-1) and a longer plasma elimination half-life (67.6 versus 54.6 min).",Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761075/),min,67.6,150799,DB01235,Levodopa
,1761075,plasma elimination half-life,"The area under the plasma concentration-time curve (AUC) of levodopa was significantly greater in the older group (547 versus 428 mumol.l-1.min in Group B), coupled with a reduced apparent oral clearance (8.1 versus 10.7 ml.min-1.kg-1) and a longer plasma elimination half-life (67.6 versus 54.6 min).",Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761075/),min,54.6,150800,DB01235,Levodopa
,1355542,systemic extraction ratio,"When L-dopa was administered into the vascular perfusate, a systemic extraction ratio of 0.38 was found, the major part being decarboxylated to dopamine.",Decarboxylation of L-dopa in the rat isolated vascularly perfused small intestine: contribution to systemic elimination and dose-dependent first pass effect. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1355542/),,0.38,150936,DB01235,Levodopa
,1355542,clearance,The intestinal L-dopa clearance was estimated to be 17.1 mL min-1 kg-1.,Decarboxylation of L-dopa in the rat isolated vascularly perfused small intestine: contribution to systemic elimination and dose-dependent first pass effect. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1355542/),[ml] / [kg·min],17.1,150937,DB01235,Levodopa
,8223831,relative bioavailability,The relative bioavailability of levodopa in the solid preparation compared to the dispersion was in all patients 100%.,Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223831/),%,100,153859,DB01235,Levodopa
<,9844789,plasma half-life,Pharmacokinetic studies yielded a plasma half-life < 5 minutes.,Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9844789/),min,5,154559,DB01235,Levodopa
,1327609,bio-availability,"Actual total daily levodopa dosage in patients treated with Sinemet CR was increased by 33%; however, the plasma level of this dosage is calculated to be similar to that of the previous dosage of Sinemet-STD (bio-availability of Sinemet CR is 71%).","Clinical efficacy of Sinemet CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open, and a double-blind, double-dummy, multicenter treatment evaluation. The Dutch Sinemet CR Study Group. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1327609/),%,71,155796,DB01235,Levodopa
,7756097,dose-corrected AUC,3. The dose-corrected AUC of levodopa after the IR-formulation was 27.5 (+/- 9.1 s.d.) ng ml-1 h per mg and 23.2 (+/- 4.6 s.d.) ng ml-1 h per mg after the CR-formulation.,Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756097/),[h·ng] / [mg·ml],27.5,157739,DB01235,Levodopa
,7756097,dose-corrected AUC,3. The dose-corrected AUC of levodopa after the IR-formulation was 27.5 (+/- 9.1 s.d.) ng ml-1 h per mg and 23.2 (+/- 4.6 s.d.) ng ml-1 h per mg after the CR-formulation.,Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756097/),[h·ng] / [mg·ml],23.2,157740,DB01235,Levodopa
,7756097,Cmax,Cmax was 1714 (+/- 1027 s.d.) ng ml-1 after the IR-formulation and 1494 (+/- 383 s.d.) ng ml-1 after the CR-formulation.,Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756097/),[ng] / [ml],1714,157741,DB01235,Levodopa
,7756097,Cmax,Cmax was 1714 (+/- 1027 s.d.) ng ml-1 after the IR-formulation and 1494 (+/- 383 s.d.) ng ml-1 after the CR-formulation.,Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756097/),[ng] / [ml],1494,157742,DB01235,Levodopa
,7756097,EC50,"Estimates of the EC50 of levodopa were 495 (+/- 144 s.d.) ng ml-1 (IR) and 1024 (+/- 502 s.d.) ng ml-1 (CR), respectively (95%-CI: 1.51-2.66, point estimator 1.95).",Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756097/),[ng] / [ml],495,157743,DB01235,Levodopa
,7756097,EC50,"Estimates of the EC50 of levodopa were 495 (+/- 144 s.d.) ng ml-1 (IR) and 1024 (+/- 502 s.d.) ng ml-1 (CR), respectively (95%-CI: 1.51-2.66, point estimator 1.95).",Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756097/),[ng] / [ml],1024,157744,DB01235,Levodopa
,7756097,duration of the motor response,"The mean duration of the motor response was 1.9 (+/- 0.5 s.d.) h (IR) and 2.8 (+/- 0.7 s.d.) h (CR), respectively (95%-CI: 1.12-2.04, point estimator 1.53).",Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756097/),h,1.9,157745,DB01235,Levodopa
,7756097,duration of the motor response,"The mean duration of the motor response was 1.9 (+/- 0.5 s.d.) h (IR) and 2.8 (+/- 0.7 s.d.) h (CR), respectively (95%-CI: 1.12-2.04, point estimator 1.53).",Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756097/),h,2.8,157746,DB01235,Levodopa
,29959802,Cmax,"L-DOPA for Cmax , AUC0-t , and AUC0-inf were 88.4 (75.9-103.1), 89.5 (84.1-95.3), and 89.6 (84.2-95.4), respectively.","Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29959802/),,88.4,157833,DB01235,Levodopa
,29959802,AUC0-t,"L-DOPA for Cmax , AUC0-t , and AUC0-inf were 88.4 (75.9-103.1), 89.5 (84.1-95.3), and 89.6 (84.2-95.4), respectively.","Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29959802/),,89.5,157834,DB01235,Levodopa
,29959802,AUC0-inf,"L-DOPA for Cmax , AUC0-t , and AUC0-inf were 88.4 (75.9-103.1), 89.5 (84.1-95.3), and 89.6 (84.2-95.4), respectively.","Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29959802/),,89.6,157835,DB01235,Levodopa
,33296447,zeta potential,The mean (SD) size of levodopa microparticles was 0.5 (0.05) µm with polydispersity index of 0.41 and a zeta potential of 10.8 mV.,Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33296447/),mv,10.8,158058,DB01235,Levodopa
,33296447,drug loading capacity,"Of the expected 20% drug loading, the actual drug loading capacity of levodopa microparticles was found to be 19.1%, giving an encapsulation efficiency of 95.7%.",Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33296447/),%,19.1,158059,DB01235,Levodopa
,33296447,AUC,In vivo pharmacokinetic studies showed that rats administered levodopa/carbidopa microparticles had greater AUC (612.7 [17.42] ng.h/mL) and higher Cmax (262.4 [38.86] ng/mL) compared with Sinemet CR: AUC 354.7 (98.09) ng.h/mL and Cmax 95.5 (20.87) ng/mL.,Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33296447/),[h·ng] / [ml],612.7,158060,DB01235,Levodopa
,33296447,Cmax,In vivo pharmacokinetic studies showed that rats administered levodopa/carbidopa microparticles had greater AUC (612.7 [17.42] ng.h/mL) and higher Cmax (262.4 [38.86] ng/mL) compared with Sinemet CR: AUC 354.7 (98.09) ng.h/mL and Cmax 95.5 (20.87) ng/mL.,Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33296447/),[ng] / [ml],262.4,158061,DB01235,Levodopa
,33296447,AUC,In vivo pharmacokinetic studies showed that rats administered levodopa/carbidopa microparticles had greater AUC (612.7 [17.42] ng.h/mL) and higher Cmax (262.4 [38.86] ng/mL) compared with Sinemet CR: AUC 354.7 (98.09) ng.h/mL and Cmax 95.5 (20.87) ng/mL.,Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33296447/),[h·ng] / [ml],354.7,158062,DB01235,Levodopa
,33296447,Cmax,In vivo pharmacokinetic studies showed that rats administered levodopa/carbidopa microparticles had greater AUC (612.7 [17.42] ng.h/mL) and higher Cmax (262.4 [38.86] ng/mL) compared with Sinemet CR: AUC 354.7 (98.09) ng.h/mL and Cmax 95.5 (20.87) ng/mL.,Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33296447/),[ng] / [ml],95.5,158063,DB01235,Levodopa
,33296447,half-life,"However, Sinemet CR had a much longer half-life (6.1 [2.58] hours) compared with levodopa/carbidopa microparticles (2.0 [0.31] hours).",Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33296447/),h,6.1,158064,DB01235,Levodopa
,33296447,half-life,"However, Sinemet CR had a much longer half-life (6.1 [2.58] hours) compared with levodopa/carbidopa microparticles (2.0 [0.31] hours).",Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33296447/),h,2.0,158065,DB01235,Levodopa
,9316692,plasma half-life,"As predicted from the plasma half-life (1.7 +/- 0.3 h) and confirmed by morning trough levels, levodopa did not accumulate when controlled released levodopa/carbidopa 25/100 was administered twice daily.",Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316692/),h,1.7,163196,DB01235,Levodopa
,17654694,C(max),"ANOVA showed the C(max) values for levodopa were not significantly different with or without sarizotan after single doses (1001 vs 1082 ng/ml; point estimate [PE] 1.10, 90% confidence intervals [CI] 0.83-1.45) or at steady-state (1549 vs 1663 ng/ml; PE 1.06, 90% CI 0.89-1.27); nor were AUC values for single doses (1661 vs 1665 ng h/ml; PE 1.01, 90% CI 0.91-1.11) or at steady-state (2462 vs 2482 ng h/ml; PE 1.01, 90% CI 0.97-1.05).",Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654694/),[ng] / [ml],1001,165310,DB01235,Levodopa
,17654694,C(max),"ANOVA showed the C(max) values for levodopa were not significantly different with or without sarizotan after single doses (1001 vs 1082 ng/ml; point estimate [PE] 1.10, 90% confidence intervals [CI] 0.83-1.45) or at steady-state (1549 vs 1663 ng/ml; PE 1.06, 90% CI 0.89-1.27); nor were AUC values for single doses (1661 vs 1665 ng h/ml; PE 1.01, 90% CI 0.91-1.11) or at steady-state (2462 vs 2482 ng h/ml; PE 1.01, 90% CI 0.97-1.05).",Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654694/),[ng] / [ml],1082,165311,DB01235,Levodopa
,17654694,C(max),"ANOVA showed the C(max) values for levodopa were not significantly different with or without sarizotan after single doses (1001 vs 1082 ng/ml; point estimate [PE] 1.10, 90% confidence intervals [CI] 0.83-1.45) or at steady-state (1549 vs 1663 ng/ml; PE 1.06, 90% CI 0.89-1.27); nor were AUC values for single doses (1661 vs 1665 ng h/ml; PE 1.01, 90% CI 0.91-1.11) or at steady-state (2462 vs 2482 ng h/ml; PE 1.01, 90% CI 0.97-1.05).",Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654694/),[ng] / [ml],1549,165312,DB01235,Levodopa
,17654694,C(max),"ANOVA showed the C(max) values for levodopa were not significantly different with or without sarizotan after single doses (1001 vs 1082 ng/ml; point estimate [PE] 1.10, 90% confidence intervals [CI] 0.83-1.45) or at steady-state (1549 vs 1663 ng/ml; PE 1.06, 90% CI 0.89-1.27); nor were AUC values for single doses (1661 vs 1665 ng h/ml; PE 1.01, 90% CI 0.91-1.11) or at steady-state (2462 vs 2482 ng h/ml; PE 1.01, 90% CI 0.97-1.05).",Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654694/),[ng] / [ml],1663,165313,DB01235,Levodopa
,17654694,AUC,"ANOVA showed the C(max) values for levodopa were not significantly different with or without sarizotan after single doses (1001 vs 1082 ng/ml; point estimate [PE] 1.10, 90% confidence intervals [CI] 0.83-1.45) or at steady-state (1549 vs 1663 ng/ml; PE 1.06, 90% CI 0.89-1.27); nor were AUC values for single doses (1661 vs 1665 ng h/ml; PE 1.01, 90% CI 0.91-1.11) or at steady-state (2462 vs 2482 ng h/ml; PE 1.01, 90% CI 0.97-1.05).",Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654694/),[h·ng] / [ml],1661,165314,DB01235,Levodopa
,17654694,AUC,"ANOVA showed the C(max) values for levodopa were not significantly different with or without sarizotan after single doses (1001 vs 1082 ng/ml; point estimate [PE] 1.10, 90% confidence intervals [CI] 0.83-1.45) or at steady-state (1549 vs 1663 ng/ml; PE 1.06, 90% CI 0.89-1.27); nor were AUC values for single doses (1661 vs 1665 ng h/ml; PE 1.01, 90% CI 0.91-1.11) or at steady-state (2462 vs 2482 ng h/ml; PE 1.01, 90% CI 0.97-1.05).",Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654694/),[h·ng] / [ml],1665,165315,DB01235,Levodopa
,17654694,AUC,"ANOVA showed the C(max) values for levodopa were not significantly different with or without sarizotan after single doses (1001 vs 1082 ng/ml; point estimate [PE] 1.10, 90% confidence intervals [CI] 0.83-1.45) or at steady-state (1549 vs 1663 ng/ml; PE 1.06, 90% CI 0.89-1.27); nor were AUC values for single doses (1661 vs 1665 ng h/ml; PE 1.01, 90% CI 0.91-1.11) or at steady-state (2462 vs 2482 ng h/ml; PE 1.01, 90% CI 0.97-1.05).",Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654694/),[h·ng] / [ml],2462,165316,DB01235,Levodopa
,17654694,AUC,"ANOVA showed the C(max) values for levodopa were not significantly different with or without sarizotan after single doses (1001 vs 1082 ng/ml; point estimate [PE] 1.10, 90% confidence intervals [CI] 0.83-1.45) or at steady-state (1549 vs 1663 ng/ml; PE 1.06, 90% CI 0.89-1.27); nor were AUC values for single doses (1661 vs 1665 ng h/ml; PE 1.01, 90% CI 0.91-1.11) or at steady-state (2462 vs 2482 ng h/ml; PE 1.01, 90% CI 0.97-1.05).",Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654694/),[h·ng] / [ml],2482,165317,DB01235,Levodopa
,28529814,Cmax,"Cmax were 372.37, 257.02, and 461.28 ng/mL and MRT were 15.36, 14.98, and 13.30 for Madopar HBS capsules, PXLNET, and IPB, respectively.",Ex Vivo and In Vivo Characterization of Interpolymeric Blend/Nanoenabled Gastroretentive Levodopa Delivery Systems. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28529814/),[ng] / [ml],372.37,166191,DB01235,Levodopa
,28529814,Cmax,"Cmax were 372.37, 257.02, and 461.28 ng/mL and MRT were 15.36, 14.98, and 13.30 for Madopar HBS capsules, PXLNET, and IPB, respectively.",Ex Vivo and In Vivo Characterization of Interpolymeric Blend/Nanoenabled Gastroretentive Levodopa Delivery Systems. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28529814/),[ng] / [ml],257.02,166192,DB01235,Levodopa
,28529814,Cmax,"Cmax were 372.37, 257.02, and 461.28 ng/mL and MRT were 15.36, 14.98, and 13.30 for Madopar HBS capsules, PXLNET, and IPB, respectively.",Ex Vivo and In Vivo Characterization of Interpolymeric Blend/Nanoenabled Gastroretentive Levodopa Delivery Systems. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28529814/),[ng] / [ml],461.28,166193,DB01235,Levodopa
,28529814,MRT,"Cmax were 372.37, 257.02, and 461.28 ng/mL and MRT were 15.36, 14.98, and 13.30 for Madopar HBS capsules, PXLNET, and IPB, respectively.",Ex Vivo and In Vivo Characterization of Interpolymeric Blend/Nanoenabled Gastroretentive Levodopa Delivery Systems. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28529814/),,15.36,166194,DB01235,Levodopa
,28529814,MRT,"Cmax were 372.37, 257.02, and 461.28 ng/mL and MRT were 15.36, 14.98, and 13.30 for Madopar HBS capsules, PXLNET, and IPB, respectively.",Ex Vivo and In Vivo Characterization of Interpolymeric Blend/Nanoenabled Gastroretentive Levodopa Delivery Systems. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28529814/),,14.98,166195,DB01235,Levodopa
,28529814,MRT,"Cmax were 372.37, 257.02, and 461.28 ng/mL and MRT were 15.36, 14.98, and 13.30 for Madopar HBS capsules, PXLNET, and IPB, respectively.",Ex Vivo and In Vivo Characterization of Interpolymeric Blend/Nanoenabled Gastroretentive Levodopa Delivery Systems. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28529814/),,13.30,166196,DB01235,Levodopa
greater,2778650,oral LD50,It was also noted that the oral LD50 value of 1 was greater than 6 g/kg in mice.,A new potential prodrug to improve the duration of L-dopa: L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778650/),[g] / [kg],6,167319,DB01235,Levodopa
,7735207,peak concentration,"The dopamine concentration in the striatum increased immediately after L-dopa injection, with the peak concentration (15.9 +/- 0.5 micrograms/g) occurring at 3 min; then it returned to the pre-medication level until 2 h at 100 mg/kg dosing.",Pharmacokinetic and pharmacodynamic studies of L-dopa in rats. Effect of L-dopa on dopamine and dopamine metabolite concentration in rat striatum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735207/),[μg] / [g],15.9,167895,DB01235,Levodopa
,33367562,limit of detection,"A precised (96.7%) and accurate (95.0%) HPLC method was validated at low UltraViolet (UV) wavelength of 208 nm that showed limit of detection and limit of quantitation of 59 and 177 ng/mL, respectively.",Rapid High-Performance Liquid Chromatography Method for Levodopa Quantitation at Low UV Wavelength: Application of Pharmacokinetics Study in Rat Following Intranasal Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33367562/),[ng] / [ml],59,168960,DB01235,Levodopa
,33367562,limit of quantitation,"A precised (96.7%) and accurate (95.0%) HPLC method was validated at low UltraViolet (UV) wavelength of 208 nm that showed limit of detection and limit of quantitation of 59 and 177 ng/mL, respectively.",Rapid High-Performance Liquid Chromatography Method for Levodopa Quantitation at Low UV Wavelength: Application of Pharmacokinetics Study in Rat Following Intranasal Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33367562/),[ng] / [ml],177,168961,DB01235,Levodopa
,33367562,bioavailability,"Pharmacokinetic parameters including bioavailability of 75 and 85% with mean residence time of 78 and 94 min were estimated for intranasal solution and thermosensitive gel using the validated HPLC method, which indicated that levodopa nasal gel may be a good alternative with appropriate pharmacokinetic outcome.",Rapid High-Performance Liquid Chromatography Method for Levodopa Quantitation at Low UV Wavelength: Application of Pharmacokinetics Study in Rat Following Intranasal Delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33367562/),%,75,168962,DB01235,Levodopa
,33367562,bioavailability,"Pharmacokinetic parameters including bioavailability of 75 and 85% with mean residence time of 78 and 94 min were estimated for intranasal solution and thermosensitive gel using the validated HPLC method, which indicated that levodopa nasal gel may be a good alternative with appropriate pharmacokinetic outcome.",Rapid High-Performance Liquid Chromatography Method for Levodopa Quantitation at Low UV Wavelength: Application of Pharmacokinetics Study in Rat Following Intranasal Delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33367562/),%,85,168963,DB01235,Levodopa
,33367562,mean residence time,"Pharmacokinetic parameters including bioavailability of 75 and 85% with mean residence time of 78 and 94 min were estimated for intranasal solution and thermosensitive gel using the validated HPLC method, which indicated that levodopa nasal gel may be a good alternative with appropriate pharmacokinetic outcome.",Rapid High-Performance Liquid Chromatography Method for Levodopa Quantitation at Low UV Wavelength: Application of Pharmacokinetics Study in Rat Following Intranasal Delivery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33367562/),min,78,168964,DB01235,Levodopa
,33367562,mean residence time,"Pharmacokinetic parameters including bioavailability of 75 and 85% with mean residence time of 78 and 94 min were estimated for intranasal solution and thermosensitive gel using the validated HPLC method, which indicated that levodopa nasal gel may be a good alternative with appropriate pharmacokinetic outcome.",Rapid High-Performance Liquid Chromatography Method for Levodopa Quantitation at Low UV Wavelength: Application of Pharmacokinetics Study in Rat Following Intranasal Delivery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33367562/),min,94,168965,DB01235,Levodopa
,15090932,Time to return to baseline,"Time to return to baseline COMT activity ranged from 6 (50 mg) to 18 hours (400 mg), following the same dose-dependent tendency.","Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090932/),h,6,170488,DB01235,Levodopa
,15090932,Time to return to baseline,"Time to return to baseline COMT activity ranged from 6 (50 mg) to 18 hours (400 mg), following the same dose-dependent tendency.","Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090932/),h,18,170489,DB01235,Levodopa
,30087157,EC50,Outcomes from each of the species evaluated indicate that the EC50 of amantadine for reducing dyskinesia range from 1025 to 1633 ng/ml (1367 ng/ml for an all-species model).,Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30087157/),[ng] / [ml],1025 to 1633,172850,DB01235,Levodopa
,30087157,EC50,Outcomes from each of the species evaluated indicate that the EC50 of amantadine for reducing dyskinesia range from 1025 to 1633 ng/ml (1367 ng/ml for an all-species model).,Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30087157/),[ng] / [ml],1367,172851,DB01235,Levodopa
,12551706,C(max),The parameter C(max) of levodopa was significantly lower and t(max) longer under postprandial conditions than under fasting conditions (mean C(max) 1.41 vs.,Effects of food on the pharmacokinetics of levodopa in a dual-release formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12551706/),,1.41,174655,DB01235,Levodopa
,12551706,t(max),2.09 mg l(-1); mean t(max) 3.1 vs. 1.0 h).,Effects of food on the pharmacokinetics of levodopa in a dual-release formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12551706/),h,3.1,174656,DB01235,Levodopa
,12551706,t(max),2.09 mg l(-1); mean t(max) 3.1 vs. 1.0 h).,Effects of food on the pharmacokinetics of levodopa in a dual-release formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12551706/),h,1.0,174657,DB01235,Levodopa
,9241095,area under the concentration-time curve (AUC),The area under the concentration-time curve (AUC) of exogenously administered levodopa increased from 1.2 in the control group to 5.9 mg l(-1) h at benserazide doses of 100-200 mg three times daily.,Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241095/),[h·mg] / [l],1.2,176234,DB01235,Levodopa
,9241095,area under the concentration-time curve (AUC),The area under the concentration-time curve (AUC) of exogenously administered levodopa increased from 1.2 in the control group to 5.9 mg l(-1) h at benserazide doses of 100-200 mg three times daily.,Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241095/),[h·mg] / [l],5.9,176235,DB01235,Levodopa
,9241095,AUC,Benserazide caused a dose-dependent increase in the AUC of 3-OMD from 7.4 to 106 mg l(-1) h at doses of 200 mg.,Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241095/),[h·mg] / [l],7,176236,DB01235,Levodopa
,9241095,AUC,Benserazide caused a dose-dependent increase in the AUC of 3-OMD from 7.4 to 106 mg l(-1) h at doses of 200 mg.,Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241095/),[h·mg] / [l],106,176237,DB01235,Levodopa
,7791104,elimination half-life,"In addition, the elimination half-life (2.66 hr) and volume of distribution by area of L-dopa in blood plasma and its AUC and t1/2 in muscle ECF (1.80 hr) were enhanced substantially.",The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791104/),h,2.66,177336,DB01235,Levodopa
,7791104,volume of distribution by area,"In addition, the elimination half-life (2.66 hr) and volume of distribution by area of L-dopa in blood plasma and its AUC and t1/2 in muscle ECF (1.80 hr) were enhanced substantially.",The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791104/),h,1.80,177337,DB01235,Levodopa
,7791104,AUC,"In addition, the elimination half-life (2.66 hr) and volume of distribution by area of L-dopa in blood plasma and its AUC and t1/2 in muscle ECF (1.80 hr) were enhanced substantially.",The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791104/),h,1.80,177338,DB01235,Levodopa
,7791104,t1/2,"In addition, the elimination half-life (2.66 hr) and volume of distribution by area of L-dopa in blood plasma and its AUC and t1/2 in muscle ECF (1.80 hr) were enhanced substantially.",The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791104/),h,1.80,177339,DB01235,Levodopa
,22751085,maximum plasma concentration (Cmax),"Mean ± SEM levodopa maximum plasma concentration (Cmax) (14.1 ± 2.9 vs 9.7 ± 1.6 μmol/L; P < 0.01), plasma concentration at 30 min (C30 min) (13.7 ± 3.0 vs 8.1 ± 2.0 μmol/L; P < 0.01), and area under the plasma concentration-time curve from 0 to 3 hours (AUC0-3 hr) (15.9 ± 3.1 vs 12.1 ± 2.4 μmol/L · hour; P < 0.05) were significantly higher after coadministration of levodopa with domperidone compared to levodopa alone.",Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22751085/),[μM] / [l],14.1,177975,DB01235,Levodopa
,22751085,maximum plasma concentration (Cmax),"Mean ± SEM levodopa maximum plasma concentration (Cmax) (14.1 ± 2.9 vs 9.7 ± 1.6 μmol/L; P < 0.01), plasma concentration at 30 min (C30 min) (13.7 ± 3.0 vs 8.1 ± 2.0 μmol/L; P < 0.01), and area under the plasma concentration-time curve from 0 to 3 hours (AUC0-3 hr) (15.9 ± 3.1 vs 12.1 ± 2.4 μmol/L · hour; P < 0.05) were significantly higher after coadministration of levodopa with domperidone compared to levodopa alone.",Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22751085/),[μM] / [l],9.7,177976,DB01235,Levodopa
,22751085,plasma concentration at 30 min (C30 min),"Mean ± SEM levodopa maximum plasma concentration (Cmax) (14.1 ± 2.9 vs 9.7 ± 1.6 μmol/L; P < 0.01), plasma concentration at 30 min (C30 min) (13.7 ± 3.0 vs 8.1 ± 2.0 μmol/L; P < 0.01), and area under the plasma concentration-time curve from 0 to 3 hours (AUC0-3 hr) (15.9 ± 3.1 vs 12.1 ± 2.4 μmol/L · hour; P < 0.05) were significantly higher after coadministration of levodopa with domperidone compared to levodopa alone.",Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22751085/),[μM] / [l],13.7,177977,DB01235,Levodopa
,22751085,plasma concentration at 30 min (C30 min),"Mean ± SEM levodopa maximum plasma concentration (Cmax) (14.1 ± 2.9 vs 9.7 ± 1.6 μmol/L; P < 0.01), plasma concentration at 30 min (C30 min) (13.7 ± 3.0 vs 8.1 ± 2.0 μmol/L; P < 0.01), and area under the plasma concentration-time curve from 0 to 3 hours (AUC0-3 hr) (15.9 ± 3.1 vs 12.1 ± 2.4 μmol/L · hour; P < 0.05) were significantly higher after coadministration of levodopa with domperidone compared to levodopa alone.",Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22751085/),[μM] / [l],8.1,177978,DB01235,Levodopa
,22751085,area under the plasma concentration-time curve from 0 to 3 hours (AUC0-3 hr),"Mean ± SEM levodopa maximum plasma concentration (Cmax) (14.1 ± 2.9 vs 9.7 ± 1.6 μmol/L; P < 0.01), plasma concentration at 30 min (C30 min) (13.7 ± 3.0 vs 8.1 ± 2.0 μmol/L; P < 0.01), and area under the plasma concentration-time curve from 0 to 3 hours (AUC0-3 hr) (15.9 ± 3.1 vs 12.1 ± 2.4 μmol/L · hour; P < 0.05) were significantly higher after coadministration of levodopa with domperidone compared to levodopa alone.",Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22751085/),[μM] / [h·l],15.9,177979,DB01235,Levodopa
,22751085,area under the plasma concentration-time curve from 0 to 3 hours (AUC0-3 hr),"Mean ± SEM levodopa maximum plasma concentration (Cmax) (14.1 ± 2.9 vs 9.7 ± 1.6 μmol/L; P < 0.01), plasma concentration at 30 min (C30 min) (13.7 ± 3.0 vs 8.1 ± 2.0 μmol/L; P < 0.01), and area under the plasma concentration-time curve from 0 to 3 hours (AUC0-3 hr) (15.9 ± 3.1 vs 12.1 ± 2.4 μmol/L · hour; P < 0.05) were significantly higher after coadministration of levodopa with domperidone compared to levodopa alone.",Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22751085/),[μM] / [h·l],12.1,177980,DB01235,Levodopa
,3428308,tmax,"The mean values for tmax were 2.4, 2.8 and 0.8 h, whereas those for Cmax were 0.25, 0.56 and 1.38 micrograms/ml for one HBS capsule, two HBS capsules and standard Madopar, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),h,2.4,183143,DB01235,Levodopa
,3428308,tmax,"The mean values for tmax were 2.4, 2.8 and 0.8 h, whereas those for Cmax were 0.25, 0.56 and 1.38 micrograms/ml for one HBS capsule, two HBS capsules and standard Madopar, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),h,2.8,183144,DB01235,Levodopa
,3428308,tmax,"The mean values for tmax were 2.4, 2.8 and 0.8 h, whereas those for Cmax were 0.25, 0.56 and 1.38 micrograms/ml for one HBS capsule, two HBS capsules and standard Madopar, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),h,0.8,183145,DB01235,Levodopa
,3428308,Cmax,"The mean values for tmax were 2.4, 2.8 and 0.8 h, whereas those for Cmax were 0.25, 0.56 and 1.38 micrograms/ml for one HBS capsule, two HBS capsules and standard Madopar, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),[μg] / [ml],0.25,183146,DB01235,Levodopa
,3428308,Cmax,"The mean values for tmax were 2.4, 2.8 and 0.8 h, whereas those for Cmax were 0.25, 0.56 and 1.38 micrograms/ml for one HBS capsule, two HBS capsules and standard Madopar, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),[μg] / [ml],0.56,183147,DB01235,Levodopa
,3428308,Cmax,"The mean values for tmax were 2.4, 2.8 and 0.8 h, whereas those for Cmax were 0.25, 0.56 and 1.38 micrograms/ml for one HBS capsule, two HBS capsules and standard Madopar, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),[μg] / [ml],1.38,183148,DB01235,Levodopa
,3428308,relative bioavailability,"The mean relative bioavailability (versus standard Madopar) was 58 and 67% (value normalized to dose) for one and two HBS capsules, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),%,58,183149,DB01235,Levodopa
,3428308,relative bioavailability,"The mean relative bioavailability (versus standard Madopar) was 58 and 67% (value normalized to dose) for one and two HBS capsules, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),%,67,183150,DB01235,Levodopa
,3428308,half-value duration,"The parameter of half-value duration (= time span where plasma concentrations are equal to or higher than the half Cmax) was on average 3.5, 3.8 and 0.8 h for one HBS capsule, two HBS capsules and standard Madopar, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),h,3.5,183151,DB01235,Levodopa
,3428308,half-value duration,"The parameter of half-value duration (= time span where plasma concentrations are equal to or higher than the half Cmax) was on average 3.5, 3.8 and 0.8 h for one HBS capsule, two HBS capsules and standard Madopar, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),h,3.8,183152,DB01235,Levodopa
,3428308,half-value duration,"The parameter of half-value duration (= time span where plasma concentrations are equal to or higher than the half Cmax) was on average 3.5, 3.8 and 0.8 h for one HBS capsule, two HBS capsules and standard Madopar, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),h,0.8,183153,DB01235,Levodopa
,3428308,tmax,"Following benserazide pretreatment the mean tmax values for levodopa were 2.8, 2.3 and 0.8 h and the mean Cmax values were 0.35, 0.60 and 1.33 micrograms/ml, respectively, for one HBS capsule, two HBS capsules and standard Madopar.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),h,2.8,183154,DB01235,Levodopa
,3428308,tmax,"Following benserazide pretreatment the mean tmax values for levodopa were 2.8, 2.3 and 0.8 h and the mean Cmax values were 0.35, 0.60 and 1.33 micrograms/ml, respectively, for one HBS capsule, two HBS capsules and standard Madopar.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),h,2.3,183155,DB01235,Levodopa
,3428308,tmax,"Following benserazide pretreatment the mean tmax values for levodopa were 2.8, 2.3 and 0.8 h and the mean Cmax values were 0.35, 0.60 and 1.33 micrograms/ml, respectively, for one HBS capsule, two HBS capsules and standard Madopar.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),h,0.8,183156,DB01235,Levodopa
,3428308,Cmax,"Following benserazide pretreatment the mean tmax values for levodopa were 2.8, 2.3 and 0.8 h and the mean Cmax values were 0.35, 0.60 and 1.33 micrograms/ml, respectively, for one HBS capsule, two HBS capsules and standard Madopar.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),[μg] / [ml],0.35,183157,DB01235,Levodopa
,3428308,Cmax,"Following benserazide pretreatment the mean tmax values for levodopa were 2.8, 2.3 and 0.8 h and the mean Cmax values were 0.35, 0.60 and 1.33 micrograms/ml, respectively, for one HBS capsule, two HBS capsules and standard Madopar.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),[μg] / [ml],0.60,183158,DB01235,Levodopa
,3428308,Cmax,"Following benserazide pretreatment the mean tmax values for levodopa were 2.8, 2.3 and 0.8 h and the mean Cmax values were 0.35, 0.60 and 1.33 micrograms/ml, respectively, for one HBS capsule, two HBS capsules and standard Madopar.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),[μg] / [ml],1.33,183159,DB01235,Levodopa
,3428308,relative bioavailability,"The relative bioavailability (versus standard Madopar) was 57 +/- 14 and 63 +/- 21% (value normalized to dose) for one and two HBS capsules, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),%,57,183160,DB01235,Levodopa
,3428308,relative bioavailability,"The relative bioavailability (versus standard Madopar) was 57 +/- 14 and 63 +/- 21% (value normalized to dose) for one and two HBS capsules, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),%,63,183161,DB01235,Levodopa
,3428308,half-value duration,"The mean values of the half-value duration were 3.6, 4.2 and 1.3 h for one HBS capsule, two HBS capsules and standard Madopar, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),h,3.6,183162,DB01235,Levodopa
,3428308,half-value duration,"The mean values of the half-value duration were 3.6, 4.2 and 1.3 h for one HBS capsule, two HBS capsules and standard Madopar, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),h,4.2,183163,DB01235,Levodopa
,3428308,half-value duration,"The mean values of the half-value duration were 3.6, 4.2 and 1.3 h for one HBS capsule, two HBS capsules and standard Madopar, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),h,1.3,183164,DB01235,Levodopa
,3428308,bioavailability,The reduced bioavailability of the HBS form (60% of that of the standard form) suggests that a higher daily dose of Madopar HBS should be used for clinical practice.,Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),%,60,183165,DB01235,Levodopa
,3322837,relative bioavailability,The clinical response to Madopar HBS was delayed and brief; the relative bioavailability was only 50%.,Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3322837/),%,50,183669,DB01235,Levodopa
,8612386,Cmax,"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[μg] / [ml],1.0,184129,DB01235,Levodopa
,8612386,Cmax,"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[μg] / [ml],2.4,184130,DB01235,Levodopa
,8612386,area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity),"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[h·mg] / [l],10.1,184131,DB01235,Levodopa
,8612386,area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity),"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[h·mg] / [l],18.3,184132,DB01235,Levodopa
,8612386,AUC[0 - infinity),"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[h·mg] / [l],17.3,184133,DB01235,Levodopa
,8612386,AUC[0 - infinity),"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[h·mg] / [l],18.3,184134,DB01235,Levodopa
,8612386,Cmax,"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[μg] / [ml],2.2,184135,DB01235,Levodopa
,8612386,Cmax,"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[μg] / [ml],2.4,184136,DB01235,Levodopa
,3085927,peak plasma Dopa concentrations,"Increasing carbidopa from a mean of 145 to 290 mg/day caused a mean increase in peak plasma Dopa concentrations from 1,893 +/- 476 to 2,733 +/- 607 ng/ml and area under the Dopa plasma concentration versus time curve of 24.6 +/- 10.0%, as well as a decrease in the time to peak plasma concentration to 0.7 +/- 0.2 versus 1.2 +/- 0.3 h.",Effect of supplemental carbidopa on bioavailability of L-dopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3085927/),[ng] / [ml],"1,893",187197,DB01235,Levodopa
,3085927,peak plasma Dopa concentrations,"Increasing carbidopa from a mean of 145 to 290 mg/day caused a mean increase in peak plasma Dopa concentrations from 1,893 +/- 476 to 2,733 +/- 607 ng/ml and area under the Dopa plasma concentration versus time curve of 24.6 +/- 10.0%, as well as a decrease in the time to peak plasma concentration to 0.7 +/- 0.2 versus 1.2 +/- 0.3 h.",Effect of supplemental carbidopa on bioavailability of L-dopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3085927/),[ng] / [ml],"2,733",187198,DB01235,Levodopa
,3085927,time to peak plasma concentration,"Increasing carbidopa from a mean of 145 to 290 mg/day caused a mean increase in peak plasma Dopa concentrations from 1,893 +/- 476 to 2,733 +/- 607 ng/ml and area under the Dopa plasma concentration versus time curve of 24.6 +/- 10.0%, as well as a decrease in the time to peak plasma concentration to 0.7 +/- 0.2 versus 1.2 +/- 0.3 h.",Effect of supplemental carbidopa on bioavailability of L-dopa. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3085927/),h,0.7,187199,DB01235,Levodopa
,3085927,time to peak plasma concentration,"Increasing carbidopa from a mean of 145 to 290 mg/day caused a mean increase in peak plasma Dopa concentrations from 1,893 +/- 476 to 2,733 +/- 607 ng/ml and area under the Dopa plasma concentration versus time curve of 24.6 +/- 10.0%, as well as a decrease in the time to peak plasma concentration to 0.7 +/- 0.2 versus 1.2 +/- 0.3 h.",Effect of supplemental carbidopa on bioavailability of L-dopa. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3085927/),h,1.2,187200,DB01235,Levodopa
,9795070,tmax,"The levodopa pharmacokinetics of the new DRF showed rapid absorption (tmax=1.1 h), followed by sustained levodopa plasma concentrations, similar to the SRF.",Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9795070/),h,1.1,188844,DB01235,Levodopa
,9795070,Cmax,"Following multi-dose administration, the peak plasma concentration of the new DRF was 90% higher compared to the SFR (Cmax=2.1 and 1.1 microg/ml, respectively).",Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9795070/),[μg] / [ml],2.1,188845,DB01235,Levodopa
,9795070,Cmax,"Following multi-dose administration, the peak plasma concentration of the new DRF was 90% higher compared to the SFR (Cmax=2.1 and 1.1 microg/ml, respectively).",Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9795070/),[μg] / [ml],1.1,188846,DB01235,Levodopa
,9795070,AUC0-infinity,"The bioavailability was significantly increased by 40% (AUC0-infinity=6.1 and 4.3 microg x h/ml, respectively).",Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9795070/),[h·μg] / [ml],6.1,188847,DB01235,Levodopa
,9795070,AUC0-infinity,"The bioavailability was significantly increased by 40% (AUC0-infinity=6.1 and 4.3 microg x h/ml, respectively).",Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9795070/),[h·μg] / [ml],4.3,188848,DB01235,Levodopa
,10492060,t1/2,"The mean t1/2 values of entacapone were 1.3 h and 1.8 h during the first and sixth days, respectively; the difference was not significant.",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,1.3,190584,DB01235,Levodopa
,10492060,t1/2,"The mean t1/2 values of entacapone were 1.3 h and 1.8 h during the first and sixth days, respectively; the difference was not significant.",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,1.8,190585,DB01235,Levodopa
,10492060,Cmax,"There were no between-day differences in Cmax, t1/2 (2.4 h on days 1-2 and 2.3 h on days 6-7) or AUC of levodopa, whereas tmax occurred at 0.8 h on day 1 and at 1.2 h on day 6 (P = 0.03).",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,2.4,190586,DB01235,Levodopa
,10492060,t1/2,"There were no between-day differences in Cmax, t1/2 (2.4 h on days 1-2 and 2.3 h on days 6-7) or AUC of levodopa, whereas tmax occurred at 0.8 h on day 1 and at 1.2 h on day 6 (P = 0.03).",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,2.4,190587,DB01235,Levodopa
,10492060,t1/2,"There were no between-day differences in Cmax, t1/2 (2.4 h on days 1-2 and 2.3 h on days 6-7) or AUC of levodopa, whereas tmax occurred at 0.8 h on day 1 and at 1.2 h on day 6 (P = 0.03).",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,2.3,190588,DB01235,Levodopa
,10492060,tmax,"There were no between-day differences in Cmax, t1/2 (2.4 h on days 1-2 and 2.3 h on days 6-7) or AUC of levodopa, whereas tmax occurred at 0.8 h on day 1 and at 1.2 h on day 6 (P = 0.03).",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,0.8,190589,DB01235,Levodopa
,10492060,tmax,"There were no between-day differences in Cmax, t1/2 (2.4 h on days 1-2 and 2.3 h on days 6-7) or AUC of levodopa, whereas tmax occurred at 0.8 h on day 1 and at 1.2 h on day 6 (P = 0.03).",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,1.2,190590,DB01235,Levodopa
,31258882,T max,"After inhalation, levodopa T max occurred within 15 min in all participants, whereas after oral administration, T max ranged from 20 min to 90 min.",Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31258882/),min,15,195986,DB01235,Levodopa
,31258882,T max,"After inhalation, levodopa T max occurred within 15 min in all participants, whereas after oral administration, T max ranged from 20 min to 90 min.",Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31258882/),min,20,195987,DB01235,Levodopa
,31258882,T max,"After inhalation, levodopa T max occurred within 15 min in all participants, whereas after oral administration, T max ranged from 20 min to 90 min.",Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31258882/),min,90,195988,DB01235,Levodopa
,31258882,bioavailability,The bioavailability of inhaled levodopa without carboxylase inhibitor was 53% relative to oral levodopa with carboxylase inhibitor.,Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31258882/),%,53,195989,DB01235,Levodopa
,23548675,run time,"To our knowledge, this is the first UHPLC-MS/MS based method that utilizes derivatization with fluorescamine and provides adequate sensitivity for both levodopa and carbidopa with 50 μL of sample and a run time of 3.5 min.",Development and validation of a simple and sensitive method for quantification of levodopa and carbidopa in rat and monkey plasma using derivatization and UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23548675/),min,3.5,200291,DB01235,Levodopa
,8527287,tmax,"5. Tolcapone was rapidly absorbed and eliminated with, on average, a tmax of 1.5 h and a t1/2 of 2.3 h.",Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527287/),h,1.5,200415,DB01235,Levodopa
,8527287,t1/2,"5. Tolcapone was rapidly absorbed and eliminated with, on average, a tmax of 1.5 h and a t1/2 of 2.3 h.",Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527287/),h,2.3,200416,DB01235,Levodopa
,9728899,concentration at half-maximal effect,"The mean concentration at half-maximal effect estimated for the different groups was as follows (mean value +/- SD): group 1, 389 +/- 138 ng x ml(-1); group 2, 346 +/- 203 ng x ml(-1); group 3, 543 +/- 245 ng x ml(-1); group 4, 711 +/- 215 ng x ml(-1).",Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728899/),[ng] / [ml],389,203783,DB01235,Levodopa
,9728899,concentration at half-maximal effect,"The mean concentration at half-maximal effect estimated for the different groups was as follows (mean value +/- SD): group 1, 389 +/- 138 ng x ml(-1); group 2, 346 +/- 203 ng x ml(-1); group 3, 543 +/- 245 ng x ml(-1); group 4, 711 +/- 215 ng x ml(-1).",Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728899/),[ng] / [ml],346,203784,DB01235,Levodopa
,9728899,concentration at half-maximal effect,"The mean concentration at half-maximal effect estimated for the different groups was as follows (mean value +/- SD): group 1, 389 +/- 138 ng x ml(-1); group 2, 346 +/- 203 ng x ml(-1); group 3, 543 +/- 245 ng x ml(-1); group 4, 711 +/- 215 ng x ml(-1).",Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728899/),[ng] / [ml],543,203785,DB01235,Levodopa
,9728899,concentration at half-maximal effect,"The mean concentration at half-maximal effect estimated for the different groups was as follows (mean value +/- SD): group 1, 389 +/- 138 ng x ml(-1); group 2, 346 +/- 203 ng x ml(-1); group 3, 543 +/- 245 ng x ml(-1); group 4, 711 +/- 215 ng x ml(-1).",Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728899/),[ng] / [ml],711,203786,DB01235,Levodopa
,9728899,maximal response,"Estimate of the maximal response was determined to be the following: group 1, 10 +/- 3; group 2, 12 +/- 5; group 3, 24 +/- 13; group 4, 18 +/- 7.",Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728899/),,10,203787,DB01235,Levodopa
,9728899,maximal response,"Estimate of the maximal response was determined to be the following: group 1, 10 +/- 3; group 2, 12 +/- 5; group 3, 24 +/- 13; group 4, 18 +/- 7.",Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728899/),,12,203788,DB01235,Levodopa
,9728899,maximal response,"Estimate of the maximal response was determined to be the following: group 1, 10 +/- 3; group 2, 12 +/- 5; group 3, 24 +/- 13; group 4, 18 +/- 7.",Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728899/),,24,203789,DB01235,Levodopa
,9728899,maximal response,"Estimate of the maximal response was determined to be the following: group 1, 10 +/- 3; group 2, 12 +/- 5; group 3, 24 +/- 13; group 4, 18 +/- 7.",Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728899/),,18,203790,DB01235,Levodopa
,2515726,concentrations,"The mean concentrations of patients with Alzheimer's or Parkinson's disease were 6.5 +/- 2.5 ng/ml for A, 14.7 +/- 6.5 ng/ml for MA and 0.9 +/- 0.7 ng/ml for DES.",Pharmacokinetics and metabolism of selegiline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515726/),[ng] / [ml],6.5,204252,DB01235,Levodopa
,2515726,concentrations,"The mean concentrations of patients with Alzheimer's or Parkinson's disease were 6.5 +/- 2.5 ng/ml for A, 14.7 +/- 6.5 ng/ml for MA and 0.9 +/- 0.7 ng/ml for DES.",Pharmacokinetics and metabolism of selegiline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515726/),[ng] / [ml],14.7,204253,DB01235,Levodopa
,2515726,concentrations,"The mean concentrations of patients with Alzheimer's or Parkinson's disease were 6.5 +/- 2.5 ng/ml for A, 14.7 +/- 6.5 ng/ml for MA and 0.9 +/- 0.7 ng/ml for DES.",Pharmacokinetics and metabolism of selegiline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515726/),[ng] / [ml],0.9,204254,DB01235,Levodopa
,2515726,recovery,"The metabolites of selegiline were excreted in urine, and the recovery as metabolites was 87%.",Pharmacokinetics and metabolism of selegiline. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515726/),%,87,204255,DB01235,Levodopa
,16327247,C(max),"When a levodopa preparation (EC-Doparl tablets) was orally administered with banana juice made by mixing with a fresh banana and water, there were significant decreases in C(max) (17.4+/-2.5 vs. 8.6+/-3.1 microg/ml; alpha=0.05) and AUC (1882.8+/-49.2 vs. 933.5+/-286.6 microg.min/ml; alpha=0.05) for levodopa.",Banana juice reduces bioavailability of levodopa preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16327247/),[μg] / [ml],17.4,204397,DB01235,Levodopa
,16327247,C(max),"When a levodopa preparation (EC-Doparl tablets) was orally administered with banana juice made by mixing with a fresh banana and water, there were significant decreases in C(max) (17.4+/-2.5 vs. 8.6+/-3.1 microg/ml; alpha=0.05) and AUC (1882.8+/-49.2 vs. 933.5+/-286.6 microg.min/ml; alpha=0.05) for levodopa.",Banana juice reduces bioavailability of levodopa preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16327247/),[μg] / [ml],8.6,204398,DB01235,Levodopa
,16327247,AUC,"When a levodopa preparation (EC-Doparl tablets) was orally administered with banana juice made by mixing with a fresh banana and water, there were significant decreases in C(max) (17.4+/-2.5 vs. 8.6+/-3.1 microg/ml; alpha=0.05) and AUC (1882.8+/-49.2 vs. 933.5+/-286.6 microg.min/ml; alpha=0.05) for levodopa.",Banana juice reduces bioavailability of levodopa preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16327247/),[min·μg] / [ml],1882.8,204399,DB01235,Levodopa
,16327247,AUC,"When a levodopa preparation (EC-Doparl tablets) was orally administered with banana juice made by mixing with a fresh banana and water, there were significant decreases in C(max) (17.4+/-2.5 vs. 8.6+/-3.1 microg/ml; alpha=0.05) and AUC (1882.8+/-49.2 vs. 933.5+/-286.6 microg.min/ml; alpha=0.05) for levodopa.",Banana juice reduces bioavailability of levodopa preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16327247/),[min·μg] / [ml],933.5,204400,DB01235,Levodopa
,32482490,Tmax,Median Tmax values with CVT-301 and oral CD/LD were 15 and 120 min (P < 0.001).,Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),min,15,205209,DB01235,Levodopa
,32482490,Tmax,Median Tmax values with CVT-301 and oral CD/LD were 15 and 120 min (P < 0.001).,Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),min,120,205210,DB01235,Levodopa
,32482490,Cmax,Cmax with CVT-301 was lower than with oral CD/LD (590.3 vs 844.3 ng/mL).,Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),[ng] / [ml],590.3,205211,DB01235,Levodopa
,32482490,Cmax,Cmax with CVT-301 was lower than with oral CD/LD (590.3 vs 844.3 ng/mL).,Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),[ng] / [ml],844.3,205212,DB01235,Levodopa
,32482490,C10min,"C10min and C30min values with CVT-301 were approximately twice those with CD/LD (522.9 and 531.5 ng/mL vs 247.3 and 300.9 ng/mL, respectively).",Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),[ng] / [ml],522.9,205213,DB01235,Levodopa
,32482490,C10min,"C10min and C30min values with CVT-301 were approximately twice those with CD/LD (522.9 and 531.5 ng/mL vs 247.3 and 300.9 ng/mL, respectively).",Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),[ng] / [ml],531.5,205214,DB01235,Levodopa
,32482490,C10min,"C10min and C30min values with CVT-301 were approximately twice those with CD/LD (522.9 and 531.5 ng/mL vs 247.3 and 300.9 ng/mL, respectively).",Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),[ng] / [ml],247.3,205215,DB01235,Levodopa
,32482490,C30min,"C10min and C30min values with CVT-301 were approximately twice those with CD/LD (522.9 and 531.5 ng/mL vs 247.3 and 300.9 ng/mL, respectively).",Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),[ng] / [ml],531.5,205216,DB01235,Levodopa
,32482490,C30min,"C10min and C30min values with CVT-301 were approximately twice those with CD/LD (522.9 and 531.5 ng/mL vs 247.3 and 300.9 ng/mL, respectively).",Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),[ng] / [ml],300.9,205217,DB01235,Levodopa
,12844325,elimination half-life,The elimination half-life of cabergoline estimated from urinary data of healthy subjects ranges between 63 and 109 hours.,Clinical pharmacokinetics of cabergoline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12844325/),h,63 and 109,210629,DB01235,Levodopa
,1773422,area under the curve [AUC],On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],2.10,215026,DB01235,Levodopa
,1773422,area under the curve [AUC],On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],4.96,215027,DB01235,Levodopa
,1773422,AUC,On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],4.05,215028,DB01235,Levodopa
,1773422,AUC,On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],1.94,215029,DB01235,Levodopa
,1773422,AUC,On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],3.91,215030,DB01235,Levodopa
,1773422,AUC,On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],3.81,215031,DB01235,Levodopa
,1490503,bioavailability,Almost equivalent bioavailability (85-90%) of levodopa was demonstrated for the controlled-release formulations relative to that of conventional Madopar capsules.,Comparative multiple-dose pharmacokinetics of controlled-release levodopa products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490503/),%,85-90,222528,DB01235,Levodopa
,10829343,minimum detectable concentration,"Using this method, the minimum detectable concentration was estimated to be 5 and 8 ng ml-1 for L-dopa and C-dopa, respectively.",Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829343/),[ng] / [ml],5,224309,DB01235,Levodopa
,10829343,minimum detectable concentration,"Using this method, the minimum detectable concentration was estimated to be 5 and 8 ng ml-1 for L-dopa and C-dopa, respectively.",Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829343/),[ng] / [ml],8,224310,DB01235,Levodopa
,10829343,Recovery,"Recovery studies ranged from 93.83 to 89.76%, with a relative standard deviation of less than 7%.",Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829343/),%,93.83 to 89.76,224311,DB01235,Levodopa
less,10829343,half-lives,"The data also indicated a very low accumulation of both levodopa and carbidopa following repeated administration of the drugs, which was consistent with their relatively short half-lives (less than 2 h).",Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829343/),h,2,224312,DB01235,Levodopa
,10829343,half-life,"In contrast, the half-life for the metabolite 3-orthomethyl dopa (3-OMD) is in the order of 13 h.",Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829343/),h,13,224313,DB01235,Levodopa
,2685649,bioavailability,"Results indicate a levodopa bioavailability of 71% for Sinemet CR, in contrast to a bioavailability of 99% for Sinemet for these subjects.",Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685649/),%,71,225396,DB01235,Levodopa
,2685649,bioavailability,"Results indicate a levodopa bioavailability of 71% for Sinemet CR, in contrast to a bioavailability of 99% for Sinemet for these subjects.",Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685649/),%,99,225397,DB01235,Levodopa
,2685649,bioavailability,The carbidopa bioavailability of Sinemet CR was 58% relative to that of Sinemet.,Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685649/),%,58,225398,DB01235,Levodopa
,19804823,absolute bioavailabilities,"The absolute bioavailabilities of oral and nasal preparations containing C-dopa were 17.7 and 45.4%, respectively.",Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19804823/),%,17.7,227456,DB01235,Levodopa
,19804823,absolute bioavailabilities,"The absolute bioavailabilities of oral and nasal preparations containing C-dopa were 17.7 and 45.4%, respectively.",Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19804823/),%,45.4,227457,DB01235,Levodopa
less,19804823,half-life,"Although the half-life after nasal administration was relatively short (less than 30 min) in both blood and brain regardless of C-dopa addition, the systemic exposure was promising due to rapid absorption.",Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19804823/),min,30,227458,DB01235,Levodopa
,20231306,peak plasma concentration,These effects were associated with a peak plasma concentration of 20.9 microM and an area under the curve from 0 to 24 h of 136.1 h x microM (36 mg/kg).,"Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20231306/),μM,20.9,227585,DB01235,Levodopa
,20231306,area under the curve from 0 to 24 h,These effects were associated with a peak plasma concentration of 20.9 microM and an area under the curve from 0 to 24 h of 136.1 h x microM (36 mg/kg).,"Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20231306/),h·μM,136.1,227586,DB01235,Levodopa
,26936272,absorption rate constant (KA),"Pharmacokinetic analysis identified a one-compartment model with the following parameter values [bootstrap 95 % CI]: absorption rate constant (KA) 1.86 1/h [1.08-3.25], clearance 36.6 L/h [31.3-42.8], and volume of distribution 42.9 L [34.3-52.3].",A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26936272/),[1] / [h],1.86,228871,DB01235,Levodopa
,26936272,clearance,"Pharmacokinetic analysis identified a one-compartment model with the following parameter values [bootstrap 95 % CI]: absorption rate constant (KA) 1.86 1/h [1.08-3.25], clearance 36.6 L/h [31.3-42.8], and volume of distribution 42.9 L [34.3-52.3].",A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26936272/),[l] / [h],36.6,228872,DB01235,Levodopa
,26936272,volume of distribution,"Pharmacokinetic analysis identified a one-compartment model with the following parameter values [bootstrap 95 % CI]: absorption rate constant (KA) 1.86 1/h [1.08-3.25], clearance 36.6 L/h [31.3-42.8], and volume of distribution 42.9 L [34.3-52.3].",A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26936272/),l,42.9,228873,DB01235,Levodopa
,26936272,Residual var,Residual variability was 1120 μg/L [886-1290].,A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26936272/),[μg] / [l],1120,228874,DB01235,Levodopa
,26936272,KE0,UPDRS III and dyskinesia were best described with an effect compartment and similar KE0 values of 1.37 1/h [1.01-1.77].,A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26936272/),[1] / [h],1.37,228875,DB01235,Levodopa
,26936272,E0,"For UPDRS III, the E0, EC50, Emax, and Hill coefficient were 31.4 [28.4-35.3], 1410 μg/L [1200-1700], 0.72 [0.71-0.75], and 4.26 [3.20-5.58], respectively.",A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26936272/),,31.4,228876,DB01235,Levodopa
,26936272,Hill coefficient,"For UPDRS III, the E0, EC50, Emax, and Hill coefficient were 31.4 [28.4-35.3], 1410 μg/L [1200-1700], 0.72 [0.71-0.75], and 4.26 [3.20-5.58], respectively.",A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26936272/),,4.26,228877,DB01235,Levodopa
,26936272,EC50,"For dyskinesia, the EC50 and Emax were 6280 μg/L [3420-37,900] and 17.9 [12.3-80.8], respectively.",A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26936272/),[μg] / [l],6280,228878,DB01235,Levodopa
,26936272,Emax,"For dyskinesia, the EC50 and Emax were 6280 μg/L [3420-37,900] and 17.9 [12.3-80.8], respectively.",A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26936272/),,17.9,228879,DB01235,Levodopa
,26936272,Residual,Residual variability was 3.15 [2.75-3.53] for UPDRS III and 2.66 [1.94-3.51] for dyskinesia.,A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26936272/),,3.15,228880,DB01235,Levodopa
,26936272,Residual,Residual variability was 3.15 [2.75-3.53] for UPDRS III and 2.66 [1.94-3.51] for dyskinesia.,A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26936272/),,2.66,228881,DB01235,Levodopa
,1904753,clearance,"2. Gludopa had a clearance of 4.43 +/- 1.50 ml min-1 kg-1 and 4.92 ml min-1 kg-1 at the higher and lower doses, respectively.",Disposition of gamma-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904753/),[ml] / [kg·min],4.43,235664,DB01235,Levodopa
,1904753,clearance,"2. Gludopa had a clearance of 4.43 +/- 1.50 ml min-1 kg-1 and 4.92 ml min-1 kg-1 at the higher and lower doses, respectively.",Disposition of gamma-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904753/),[ml] / [kg·min],4.92,235665,DB01235,Levodopa
,1904753,half-lives,"Corresponding half-lives were 29.2 +/- 3.7 min and 32.5 +/- 5.6 min, and volumes of distribution were 0.183 +/- 0.052 l kg-1 and 0.235 +/- 0.07/ l kg-1.",Disposition of gamma-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904753/),min,29.2,235666,DB01235,Levodopa
,1904753,half-lives,"Corresponding half-lives were 29.2 +/- 3.7 min and 32.5 +/- 5.6 min, and volumes of distribution were 0.183 +/- 0.052 l kg-1 and 0.235 +/- 0.07/ l kg-1.",Disposition of gamma-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904753/),min,32.5,235667,DB01235,Levodopa
,1904753,volumes of distribution,"Corresponding half-lives were 29.2 +/- 3.7 min and 32.5 +/- 5.6 min, and volumes of distribution were 0.183 +/- 0.052 l kg-1 and 0.235 +/- 0.07/ l kg-1.",Disposition of gamma-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904753/),[l] / [kg],0.183,235668,DB01235,Levodopa
,1904753,volumes of distribution,"Corresponding half-lives were 29.2 +/- 3.7 min and 32.5 +/- 5.6 min, and volumes of distribution were 0.183 +/- 0.052 l kg-1 and 0.235 +/- 0.07/ l kg-1.",Disposition of gamma-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904753/),1/[kg·l],0.235,235669,DB01235,Levodopa
,14718682,bioavailability,"In switching patients who are receiving levodopa/carbidopa controlled-release (CR), it should be noted that the bioavailability of levodopa from levodopa/carbidopa CR is approximately 70-75% that of levodopa/carbidopa IR products, including Stalevo.",Levodopa/carbidopa/entacapone (Stalevo). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14718682/),%,70-75,236483,DB01235,Levodopa
,27137718,tmax,"After a single oral administrations of 50 and 800 mg opicapone, opicapone was the major entity in the circulation, with a median tmax of 1.5-2.0 hours.",Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137718/),h,1.5-2.0,236675,DB01235,Levodopa
,27137718,elimination half-life,"Opicapone was rapidly eliminated, with an elimination half-life of 1-2 hours.",Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137718/),h,1-2,236676,DB01235,Levodopa
,34018344,plasma half-life,"Pharmacokinetic analysis indicated rapid absorption and dose-linear pharmacokinetics of mesdopetam, with a plasma half-life of around 7 h, upon single and repeated dosing.","A first-in-human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34018344/),h,7,237731,DB01235,Levodopa
,16139166,AUC,"The extent of levodopa absorbed when administering 100 mg/kg of fiber (AUC=43.4 mug min ml(-1)) is approximately the same as when levodopa is administered alone (AUC=47.1 microg min ml(-1)); however, Cmax is lower (1.04 versus 1.43 microg ml(-1)).",Hydrosoluble fiber (Plantago ovata husk) and levodopa I: experimental study of the pharmacokinetic interaction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16139166/),[min·μg] / [ml],43.4,239238,DB01235,Levodopa
,16139166,AUC,"The extent of levodopa absorbed when administering 100 mg/kg of fiber (AUC=43.4 mug min ml(-1)) is approximately the same as when levodopa is administered alone (AUC=47.1 microg min ml(-1)); however, Cmax is lower (1.04 versus 1.43 microg ml(-1)).",Hydrosoluble fiber (Plantago ovata husk) and levodopa I: experimental study of the pharmacokinetic interaction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16139166/),[min·μg] / [ml],47.1,239239,DB01235,Levodopa
,16139166,Cmax,"The extent of levodopa absorbed when administering 100 mg/kg of fiber (AUC=43.4 mug min ml(-1)) is approximately the same as when levodopa is administered alone (AUC=47.1 microg min ml(-1)); however, Cmax is lower (1.04 versus 1.43 microg ml(-1)).",Hydrosoluble fiber (Plantago ovata husk) and levodopa I: experimental study of the pharmacokinetic interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16139166/),[μg] / [ml],1.04,239240,DB01235,Levodopa
,16139166,Cmax,"The extent of levodopa absorbed when administering 100 mg/kg of fiber (AUC=43.4 mug min ml(-1)) is approximately the same as when levodopa is administered alone (AUC=47.1 microg min ml(-1)); however, Cmax is lower (1.04 versus 1.43 microg ml(-1)).",Hydrosoluble fiber (Plantago ovata husk) and levodopa I: experimental study of the pharmacokinetic interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16139166/),[μg] / [ml],1.43,239241,DB01235,Levodopa
,16139166,AUC,"Results obtained indicate that fiber at the higher dose increases the extent of levodopa absorbed (AUC=62.2 microg min ml(-1)), being the value of Cmax similar (1.46 microg ml(-1)).",Hydrosoluble fiber (Plantago ovata husk) and levodopa I: experimental study of the pharmacokinetic interaction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16139166/),[min·μg] / [ml],62.2,239242,DB01235,Levodopa
,16139166,Cmax,"Results obtained indicate that fiber at the higher dose increases the extent of levodopa absorbed (AUC=62.2 microg min ml(-1)), being the value of Cmax similar (1.46 microg ml(-1)).",Hydrosoluble fiber (Plantago ovata husk) and levodopa I: experimental study of the pharmacokinetic interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16139166/),[μg] / [ml],1.46,239243,DB01235,Levodopa
,16139166,tmax,The value of tmax increases from 10 min when levodopa is administered alone to 20 min when the animals receive fiber.,Hydrosoluble fiber (Plantago ovata husk) and levodopa I: experimental study of the pharmacokinetic interaction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16139166/),min,10,239244,DB01235,Levodopa
,16139166,tmax,The value of tmax increases from 10 min when levodopa is administered alone to 20 min when the animals receive fiber.,Hydrosoluble fiber (Plantago ovata husk) and levodopa I: experimental study of the pharmacokinetic interaction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16139166/),min,20,239245,DB01235,Levodopa
,24363125,absolute bioavailabilities,"The absolute bioavailabilities of nasal preparations with and without Carbopol were 82.4 and 66.7 %, respectively, which were much higher than that of oral delivery (16.2 %).",Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24363125/),%,82.4,244438,DB01235,Levodopa
,24363125,absolute bioavailabilities,"The absolute bioavailabilities of nasal preparations with and without Carbopol were 82.4 and 66.7 %, respectively, which were much higher than that of oral delivery (16.2 %).",Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24363125/),%,66.7,244439,DB01235,Levodopa
,24363125,absolute bioavailabilities,"The absolute bioavailabilities of nasal preparations with and without Carbopol were 82.4 and 66.7 %, respectively, which were much higher than that of oral delivery (16.2 %).",Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24363125/),%,16.2,244440,DB01235,Levodopa
,27214664,tmax,Dipraglurant was rapidly absorbed (tmax = 1 hour).,A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27214664/),h,1,246701,DB01235,Levodopa
,27214664,Cmax,The 100-mg dose led to a mean Cmax of 1844 ng/mL on day 28.,A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27214664/),[ng] / [ml],1844,246702,DB01235,Levodopa
,2774511,distribution half-life,"In 11 of 15 subjects, the disappearance of drug could be described by a two-compartment model, with a distribution half-life of 5 minutes and an elimination half-life of 33 minutes.",Peripheral pharmacokinetics of apomorphine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2774511/),min,5,247981,DB01235,Levodopa
,2774511,elimination half-life,"In 11 of 15 subjects, the disappearance of drug could be described by a two-compartment model, with a distribution half-life of 5 minutes and an elimination half-life of 33 minutes.",Peripheral pharmacokinetics of apomorphine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2774511/),min,33,247982,DB01235,Levodopa
,2775615,plasma clearance,2. The plasma clearance of levodopa following intravenous administration of 50 mg was 14.2 +/- 2.8 (s.d.) ml min-1 kg-1 in the elderly compared with 23.4 +/- 4.1 ml min-1 kg-1 in the young (P less than 0.01) which resulted in a 49% greater area under the plasma concentration-time curve (AUC) in the older subjects (P less than 0.01).,The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),[ml] / [kg·min],14.2,249584,DB01235,Levodopa
,2775615,plasma clearance,2. The plasma clearance of levodopa following intravenous administration of 50 mg was 14.2 +/- 2.8 (s.d.) ml min-1 kg-1 in the elderly compared with 23.4 +/- 4.1 ml min-1 kg-1 in the young (P less than 0.01) which resulted in a 49% greater area under the plasma concentration-time curve (AUC) in the older subjects (P less than 0.01).,The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),[ml] / [kg·min],23.4,249585,DB01235,Levodopa
,2775615,volume of distribution (Vss),The volume of distribution (Vss) was lower in the elderly (1.01 +/- 0.29 l kg-1) than in the young (1.65 +/- 0.39 l kg-1) (P less than 0.002).,The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),[l] / [kg],1.01,249586,DB01235,Levodopa
,2775615,volume of distribution (Vss),The volume of distribution (Vss) was lower in the elderly (1.01 +/- 0.29 l kg-1) than in the young (1.65 +/- 0.39 l kg-1) (P less than 0.002).,The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),[l] / [kg],1.65,249587,DB01235,Levodopa
,2775615,AUC,3. Following oral administration of 250 mg of levodopa the AUC was 2512 +/- 588 ng ml-1h in the elderly compared with 1056 +/- 282 ng ml-1h in the young (P less than 0.002).,The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),[ng] / [ml],2512,249588,DB01235,Levodopa
,2775615,AUC,3. Following oral administration of 250 mg of levodopa the AUC was 2512 +/- 588 ng ml-1h in the elderly compared with 1056 +/- 282 ng ml-1h in the young (P less than 0.002).,The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),[ng] / [ml],1056,249589,DB01235,Levodopa
,2775615,bioavailability,"The bioavailability of levodopa was significantly greater in the elderly (0.63 +/- 0.12 compared with 0.41 +/- 0.16, P less than 0.01).",The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),,0.63,249590,DB01235,Levodopa
,2775615,bioavailability,"The bioavailability of levodopa was significantly greater in the elderly (0.63 +/- 0.12 compared with 0.41 +/- 0.16, P less than 0.01).",The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),,0.41,249591,DB01235,Levodopa
,2775615,plasma clearance,"4. In the presence of carbidopa, the plasma clearance of intravenous levodopa (50 mg) was reduced in both age groups but remained lower in the elderly (5.8 +/- 0.9 ml min-1 kg-1 compared with 9.3 +/- 1.0 ml min-1 kg-1; P less than 0.01).",The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),[ml] / [kg·min],5.8,249592,DB01235,Levodopa
,2775615,plasma clearance,"4. In the presence of carbidopa, the plasma clearance of intravenous levodopa (50 mg) was reduced in both age groups but remained lower in the elderly (5.8 +/- 0.9 ml min-1 kg-1 compared with 9.3 +/- 1.0 ml min-1 kg-1; P less than 0.01).",The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),[ml] / [kg·min],9.3,249593,DB01235,Levodopa
,25112783,Cmax,"Levodopa Cmax was very similar in the initial situation (603.2 ng/ml) and after placebo administration (612.0 ng/ml), being slightly lower (547.8 ng/ml) when Plantago ovata husk was given.",A randomised clinical trial to evaluate the effects of Plantago ovata husk in Parkinson patients: changes in levodopa pharmacokinetics and biochemical parameters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25112783/),[ng] / [ml],603.2,249714,DB01235,Levodopa
,25112783,Cmax,"Levodopa Cmax was very similar in the initial situation (603.2 ng/ml) and after placebo administration (612.0 ng/ml), being slightly lower (547.8 ng/ml) when Plantago ovata husk was given.",A randomised clinical trial to evaluate the effects of Plantago ovata husk in Parkinson patients: changes in levodopa pharmacokinetics and biochemical parameters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25112783/),[ng] / [ml],612.0,249715,DB01235,Levodopa
,25112783,Cmax,"Levodopa Cmax was very similar in the initial situation (603.2 ng/ml) and after placebo administration (612.0 ng/ml), being slightly lower (547.8 ng/ml) when Plantago ovata husk was given.",A randomised clinical trial to evaluate the effects of Plantago ovata husk in Parkinson patients: changes in levodopa pharmacokinetics and biochemical parameters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25112783/),[ng] / [ml],547.8,249716,DB01235,Levodopa
,25112783,AUC,"AUC was very similar in the three groups: initial situation.- 62.87 μg.min/ml, fiber treatment.- 64.47 μg.min/ml and placebo treatment.- 65.10 μg.min/ml.",A randomised clinical trial to evaluate the effects of Plantago ovata husk in Parkinson patients: changes in levodopa pharmacokinetics and biochemical parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25112783/),[min·μg] / [ml],62.87,249717,DB01235,Levodopa
,11847938,maximum concentration (Cmax),"The maximum concentration (Cmax) values of brasofensine observed in plasma after oral administration were 0.35, 0.82, 2.14, and 3.27 ng/mL for the 0.5-, 1-, 2-, and 4-mg doses, respectively; these concentrations occurred 4 hours (time to Cmax) after administration in all cases.",Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847938/),[ng] / [ml],0.35,251269,DB01235,Levodopa
,11847938,maximum concentration (Cmax),"The maximum concentration (Cmax) values of brasofensine observed in plasma after oral administration were 0.35, 0.82, 2.14, and 3.27 ng/mL for the 0.5-, 1-, 2-, and 4-mg doses, respectively; these concentrations occurred 4 hours (time to Cmax) after administration in all cases.",Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847938/),[ng] / [ml],0.82,251270,DB01235,Levodopa
,11847938,maximum concentration (Cmax),"The maximum concentration (Cmax) values of brasofensine observed in plasma after oral administration were 0.35, 0.82, 2.14, and 3.27 ng/mL for the 0.5-, 1-, 2-, and 4-mg doses, respectively; these concentrations occurred 4 hours (time to Cmax) after administration in all cases.",Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847938/),[ng] / [ml],2.14,251271,DB01235,Levodopa
,11847938,maximum concentration (Cmax),"The maximum concentration (Cmax) values of brasofensine observed in plasma after oral administration were 0.35, 0.82, 2.14, and 3.27 ng/mL for the 0.5-, 1-, 2-, and 4-mg doses, respectively; these concentrations occurred 4 hours (time to Cmax) after administration in all cases.",Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847938/),[ng] / [ml],3.27,251272,DB01235,Levodopa
,11847938,time to Cmax,"The maximum concentration (Cmax) values of brasofensine observed in plasma after oral administration were 0.35, 0.82, 2.14, and 3.27 ng/mL for the 0.5-, 1-, 2-, and 4-mg doses, respectively; these concentrations occurred 4 hours (time to Cmax) after administration in all cases.",Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847938/),h,4,251273,DB01235,Levodopa
,2720699,Half-times,"Half-times for the equilibration between plasma and the effect compartment were 0.39 h for tapping, 0.36 h for walking, and 0.34 h for the global score.",Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720699/),h,0.39,254017,DB01235,Levodopa
,2720699,Half-times,"Half-times for the equilibration between plasma and the effect compartment were 0.39 h for tapping, 0.36 h for walking, and 0.34 h for the global score.",Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720699/),h,0.36,254018,DB01235,Levodopa
,2720699,Half-times,"Half-times for the equilibration between plasma and the effect compartment were 0.39 h for tapping, 0.36 h for walking, and 0.34 h for the global score.",Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720699/),h,0.34,254019,DB01235,Levodopa
,2720699,Emax,"Pharmacodynamic data were fit best with an Emax model with baseline effect for tapping (Emax = 53.2 taps/60 s, EC50 = 0.58 microgram/ml) and global score (Emax set at 5.0 by limits of scale, EC50 = 2.53 micrograms/ml).",Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720699/),[taps] / [60·s],53.2,254020,DB01235,Levodopa
,2720699,EC50,"Pharmacodynamic data were fit best with an Emax model with baseline effect for tapping (Emax = 53.2 taps/60 s, EC50 = 0.58 microgram/ml) and global score (Emax set at 5.0 by limits of scale, EC50 = 2.53 micrograms/ml).",Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720699/),[μg] / [ml],0.58,254021,DB01235,Levodopa
,2720699,Emax,"Pharmacodynamic data were fit best with an Emax model with baseline effect for tapping (Emax = 53.2 taps/60 s, EC50 = 0.58 microgram/ml) and global score (Emax set at 5.0 by limits of scale, EC50 = 2.53 micrograms/ml).",Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720699/),,5.0,254022,DB01235,Levodopa
,2720699,EC50,"Pharmacodynamic data were fit best with an Emax model with baseline effect for tapping (Emax = 53.2 taps/60 s, EC50 = 0.58 microgram/ml) and global score (Emax set at 5.0 by limits of scale, EC50 = 2.53 micrograms/ml).",Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720699/),[μg] / [ml],2.53,254023,DB01235,Levodopa
,8748619,elimination half life,"Apomorphine is lipophilic; it has a large volume of distribution and is rapidly cleared from plasma, with an elimination half life of 33 minutes.",Pharmacokinetics of apomorphine in Parkinson's disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8748619/),min,33,255582,DB01235,Levodopa
,7888597,terminal half-life,"The mean terminal half-life, volume of distribution of the central compartment, and systemic clearance of selegiline were 60.24 +/- 9.56 min, 6.56 +/- 0.56 L kg-1, and 159.91 +/- 19.28 mL min-1 kg-1, respectively.",The pharmacokinetics and absolute bioavailability of selegiline in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7888597/),min,60.24,259906,DB01235,Levodopa
,7888597,volume of distribution of the central compartment,"The mean terminal half-life, volume of distribution of the central compartment, and systemic clearance of selegiline were 60.24 +/- 9.56 min, 6.56 +/- 0.56 L kg-1, and 159.91 +/- 19.28 mL min-1 kg-1, respectively.",The pharmacokinetics and absolute bioavailability of selegiline in the dog. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7888597/),[l] / [kg],6.56,259907,DB01235,Levodopa
,7888597,systemic clearance,"The mean terminal half-life, volume of distribution of the central compartment, and systemic clearance of selegiline were 60.24 +/- 9.56 min, 6.56 +/- 0.56 L kg-1, and 159.91 +/- 19.28 mL min-1 kg-1, respectively.",The pharmacokinetics and absolute bioavailability of selegiline in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7888597/),[ml] / [kg·min],159.91,259908,DB01235,Levodopa
,7888597,tmax,"After oral administration selegiline appeared to be absorbed rapidly with a tmax and Cmax of 25 +/- 5.8 min and 5.2 +/- 1.36 ng mL-1, respectively.",The pharmacokinetics and absolute bioavailability of selegiline in the dog. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7888597/),min,25,259909,DB01235,Levodopa
,7888597,Cmax,"After oral administration selegiline appeared to be absorbed rapidly with a tmax and Cmax of 25 +/- 5.8 min and 5.2 +/- 1.36 ng mL-1, respectively.",The pharmacokinetics and absolute bioavailability of selegiline in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7888597/),[ng] / [ml],5.2,259910,DB01235,Levodopa
,7888597,absolute bioavailability,The absolute bioavailability of selegiline in the dog was 8.51 +/- 3.31%.,The pharmacokinetics and absolute bioavailability of selegiline in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7888597/),%,8.51,259911,DB01235,Levodopa
,30290160,Maximal inhibition,"Maximal inhibition was 13.1%, 76.4% and 93.2% at 1, 10 and 100 mg/kg respectively, and COMT remained significantly inhibited at 24 h after 10 and 100 mg/kg (42.6% and 60.2% respectively).",Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30290160/),%,13.1,261679,DB01235,Levodopa
,30290160,Maximal inhibition,"Maximal inhibition was 13.1%, 76.4% and 93.2% at 1, 10 and 100 mg/kg respectively, and COMT remained significantly inhibited at 24 h after 10 and 100 mg/kg (42.6% and 60.2% respectively).",Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30290160/),%,76.4,261680,DB01235,Levodopa
,30290160,Maximal inhibition,"Maximal inhibition was 13.1%, 76.4% and 93.2% at 1, 10 and 100 mg/kg respectively, and COMT remained significantly inhibited at 24 h after 10 and 100 mg/kg (42.6% and 60.2% respectively).",Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30290160/),%,93.2,261681,DB01235,Levodopa
,30290160,Maximal inhibition,"Maximal inhibition was 13.1%, 76.4% and 93.2% at 1, 10 and 100 mg/kg respectively, and COMT remained significantly inhibited at 24 h after 10 and 100 mg/kg (42.6% and 60.2% respectively).",Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30290160/),%,42.6,261682,DB01235,Levodopa
,30290160,Maximal inhibition,"Maximal inhibition was 13.1%, 76.4% and 93.2% at 1, 10 and 100 mg/kg respectively, and COMT remained significantly inhibited at 24 h after 10 and 100 mg/kg (42.6% and 60.2% respectively).",Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30290160/),%,60.,261683,DB01235,Levodopa
,8370571,Tmax,"After an SC injection in the abdominal wall, the Tmax was brief (16 +/- 11 min) the drug was rapidly cleared from the plasma and had a short plasma half-life (69.7 +/- 25.8 min).",Pharmacokinetics of apomorphine in parkinsonian patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8370571/),min,16,266247,DB01235,Levodopa
,8370571,plasma half-life,"After an SC injection in the abdominal wall, the Tmax was brief (16 +/- 11 min) the drug was rapidly cleared from the plasma and had a short plasma half-life (69.7 +/- 25.8 min).",Pharmacokinetics of apomorphine in parkinsonian patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8370571/),min,69.7,266248,DB01235,Levodopa
,18303486,ON time,"After the levodopa test doses, ON time significantly increased 29 minutes with 75 mg nebicapone, 45 minutes with 150 mg nebicapone, and 16 minutes with 200 mg entacapone.","Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18303486/),min,29,266411,DB01235,Levodopa
,18303486,ON time,"After the levodopa test doses, ON time significantly increased 29 minutes with 75 mg nebicapone, 45 minutes with 150 mg nebicapone, and 16 minutes with 200 mg entacapone.","Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18303486/),min,45,266412,DB01235,Levodopa
,18303486,ON time,"After the levodopa test doses, ON time significantly increased 29 minutes with 75 mg nebicapone, 45 minutes with 150 mg nebicapone, and 16 minutes with 200 mg entacapone.","Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18303486/),min,16,266413,DB01235,Levodopa
,8112370,area under the plasma concentration curve (AUC),"Entacapone significantly increased the mean area under the plasma concentration curve (AUC) of levodopa by 46%, from 3620 to 5280 h.ng.ml-1 and prolonged its elimination half-life (t1/2el) from 1.5 h to 2.0 h.","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),[h·ng] / [ml],3620,266437,DB01235,Levodopa
,8112370,area under the plasma concentration curve (AUC),"Entacapone significantly increased the mean area under the plasma concentration curve (AUC) of levodopa by 46%, from 3620 to 5280 h.ng.ml-1 and prolonged its elimination half-life (t1/2el) from 1.5 h to 2.0 h.","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),[h·ng] / [ml],52,266438,DB01235,Levodopa
,8112370,elimination half-life (t1/2el),"Entacapone significantly increased the mean area under the plasma concentration curve (AUC) of levodopa by 46%, from 3620 to 5280 h.ng.ml-1 and prolonged its elimination half-life (t1/2el) from 1.5 h to 2.0 h.","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),h,1.5,266439,DB01235,Levodopa
,8112370,elimination half-life (t1/2el),"Entacapone significantly increased the mean area under the plasma concentration curve (AUC) of levodopa by 46%, from 3620 to 5280 h.ng.ml-1 and prolonged its elimination half-life (t1/2el) from 1.5 h to 2.0 h.","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),h,2.0,266440,DB01235,Levodopa
,8112370,AUC,"The mean AUC of 3,4-dihydroxyphenylacetic acid (DOPAC), the monoamine oxidase-dependent metabolite of levodopa, was significantly increased from 122 to 343 h.micrograms.","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),h·μg,122,266441,DB01235,Levodopa
,8112370,AUC,"The mean AUC of 3,4-dihydroxyphenylacetic acid (DOPAC), the monoamine oxidase-dependent metabolite of levodopa, was significantly increased from 122 to 343 h.micrograms.","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),h·μg,343,266442,DB01235,Levodopa
,8112370,AUC,"A small decrease in the AUC of homovanillic acid (HVA), the COMT dependent metabolite of levodopa, was observed (from 455 to 303 h.ng.ml-1).","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),[h·ng] / [ml],455,266443,DB01235,Levodopa
,8112370,AUC,"A small decrease in the AUC of homovanillic acid (HVA), the COMT dependent metabolite of levodopa, was observed (from 455 to 303 h.ng.ml-1).","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),[h·ng] / [ml],303,266444,DB01235,Levodopa
,1516606,time to 90% emptying,The time to 90% emptying on the gamma scan was increased significantly from 40 min to 65 min in the presence of levodopa.,The influence of levodopa on gastric emptying in healthy elderly volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516606/),min,40,269805,DB01235,Levodopa
,1516606,time to 90% emptying,The time to 90% emptying on the gamma scan was increased significantly from 40 min to 65 min in the presence of levodopa.,The influence of levodopa on gastric emptying in healthy elderly volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516606/),min,65,269806,DB01235,Levodopa
,27163503,Maximum,Maximum S-COMT inhibition (Emax ) ranged from 67.8% (25 mg OPC) to 100% (100 mg OPC).,"Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27163503/),%,67.8,270904,DB01235,Levodopa
,27163503,Maximum,Maximum S-COMT inhibition (Emax ) ranged from 67.8% (25 mg OPC) to 100% (100 mg OPC).,"Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27163503/),%,100,270905,DB01235,Levodopa
,25316499,IC50,"In vitro, AFQ056/mavoglurant had an IC50 of 30 nM in a functional assay with human mGluR5 and was selective over the other mGluR subtypes, iGluRs and a panel of 238 CNS relevant receptors, transporter or enzymes.","AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25316499/),nM,30,273800,DB01235,Levodopa
